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ABSTRACT OF DISSERTATION 
 
 
NEUROPILIN IN THE VASCULAR SYSTEM: MECHANISTIC BASIS OF 
ANGIOGENESIS 
 
The vascular system is critical for maintaining homeostasis in all vertebrates. The 
development and function of this essential network is tightly regulated by 
diffusible cytokines. Interestingly, two families of Nrp-1 ligands, Vascular 
Endothelial Growth Factor A (VEGF-A) and Semaphorin3F (Sema3F), physically 
compete for binding to the Nrp-1 b1 domain, and have opposite roles in 
regulating angiogenesis. Indeed, VEGF-A is a potent pro-angiogenic cytokine 
while Sema3F is an angiogenesis inhibitor. Although the interaction between 
VEGF and Nrp-1 is well characterized, little is known about the physical basis of 
Sema3F binding to Nrp-1. By utilizing chemically synthesized peptides and plate-
based binding assays, we showed that Sema3F C-terminal ligand binding motif 
(C-furSema) binding to Nrp1 requires engagement of two distinct binding sites on 
the Nrp-1: a C-terminal arginine binding motif and a helical binding motif. 
Covalent tethering of these two motifs leads to synergistic binding to Nrp-1. In 
addition, the helical motif was shown to be conserved in all Sema3 family 
members, suggesting this tethering mode is widely utilized. By using the natural 
variants of Sema3A, we further demonstrated that the distance between this 
helical region and the C-terminal arginine determines binding affinity. Finally, we 
showed that C-furSema potently inhibits VEGF-A signaling in human umbilical 
vein endothelial cells (HUVECs). These data provide a basis for the rational 
design of novel high affinity Nrp-1 inhibitor. 
 
VEGF functions via two essential cell surface receptor families: VEGF receptor 
(VEGFR) and Neuropilin (Nrp). Although Nrp1 is a mandatory co-receptor for 
VEGF-A-mediated angiogenesis, little is known about the specific role of Nrp-1 
and the physical basis of its function. By utilizing biochemical and biophysical 
tools, we demonstrated that Nrp-1 b1b2 domain directly interacts with the 
VEGFR-2 membrane proximal domain 7. This suggested that Nrp-1 promotes full 
VEGFR-2 activation by direct coupling to the active form of VEGFR-2 domain 7. 
Indeed, we further demonstrated that disrupting the interaction between Nrp-1 
b1b2 domain and VEGFR-2 domain 7 decreases VEGFR-2 activation upon 
VEGF-A stimulation. This defines the molecular mechanism of Nrp-1 in VEGFR-2 
activation. This also provides a novel mechanism to inhibit VEGFR-2 signaling. 
 
 
 
KEYWORDS: VEGF, receptor coupling, endothelial cells, semaphorin, X-ray 
crystallography 
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CHAPTER ONE 
 
 Vascular Development, Function and Maintenance  
 
General Introduction 
The closed circulatory system is a highly specialized organ system in vertebrates 
that transports oxygen and nutrients to the parts of the bodies where they are 
consumed, and helps to get rid of the waste products produced, such as carbon 
dioxide. This efficient pressurized vascular system greatly accelerates the 
metabolism of animals and provides a platform to support the functionalities of 
energy demanding tissues/organs, such as muscle, heart, and the central 
nervous system. In addition, the circulatory system also regulates immune 
function, body temperature and pH.  
Since the circulatory system plays critical roles, most cells in an organism are 
located within 50–100 µm of a capillary. Interestingly, the vasculature is not a 
static structure, but undergoes constant remodeling not only during development, 
but also in adulthood under physiological and pathological conditions, such as 
wound healing, cancer and wet macular degeneration. Because it has essential 
roles in human physiology and pathology, the vascular system has already been 
studied in early human history. Indeed, the first written record of the vasculature 
can be dated to 3,500 years ago in an Egyptian book named Ebers Papyrus (1). 
However, the physiological and molecular details underlying the vascular system 
has only been described until the last century. Based on decades of research, we 
now have produced a model of the process of circulatory system development 
and homeostasis. 
	  
Vasculogenesis, angiogenesis and VEGF 
The development of the vascular system is an early step in organogenesis, which 
starts from the aggregation of angioblasts, vascular precursor cells, into a 
primitive vascular plexus, a process that is called vasculogenesis. This is 
followed by a complicated remodeling process named angiogenesis, during 
which blood vessels split and sprout to form a functional circulatory system. 
Vasculogenesis is absolutely essential during development for the formation of 
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central vessels but has also been shown to take place in adults. Angiogenesis is 
not only important during development, but also plays a critical role in the 
maintenance of vasculature and wound healing. 
Intensive research has been done to study how angiogenesis is regulated on a 
molecular level. Groundbreaking work was performed by Michaelson in 1948 (2). 
Based on his own research on retinal angiogenesis during development, he 
argued that an unknown factor, named tissue factor X, forms a concentration 
gradient in the area in need of blood vessels, and new blood vessels are formed 
toward the initiating tissue. At the same time, it was reported that tumor cells are 
able to attract blood vessels suggesting that they secret a tissue factor X. Indeed, 
in 1971, Folkman demonstrated that a protein fraction around 40 kDa isolated 
from tumor cell lysate is able to activate angiogenesis, which was then named 
tumor angiogenesis factor based on its function (3). Later on, in 1989, Ferrara 
independently identified a cytokine from tumor cells and sequenced its DNA (4). 
Since this factor is able to stimulate endothelial cell proliferation, it was named 
Vascular Endothelial Growth Factor (VEGF), again based on its function. 
Interestingly, it was finally established that VEGF plays a critical role in 
angiogenesis in all these settings.  
Vasculogenesis and angiogenesis are driven by hypoxia. When tissues face the 
challenge of hypoxia, the degradation of a widely expressed oxygen sensor 
hypoxia-inducible factor (HIF) is inhibited (5, 6). The accumulation of HIF 
transcriptional complex turns on the expression of a variety of hypoxia response 
genes, such as VEGF (7). The formation of VEGF gradient in tissues regulates 
vasculogenesis and angiogenesis (Figure 1.1). The critical roles of VEGF in 
vasculogenesis and angiogenesis during early development have been 
demonstrated using transgenic mice (8, 9). The knockout of a single VEGF allele 
results in embryonic lethality due to cardiovascular defects. Interestingly, VEGF 
was the first haplo-insufficient gene identified. In addition to the first member of 
the VEGF ligand family, now known as VEGF-A, vertebrates also possess four 
other VEGF family members, VEGF-B,-C,-D, and placental growth factor (PlGF) 
(10).  The different family members appear to have both unique and partially 
overlapping functions.  It is thought that angiogenesis is primarily regulated by 
VEGF-A, -B, and PlGF, whereas lymphangiogenesis is regulated by VEGF-C 
and –D (11).  
 
The receptors of VEGF: VEGF receptor and Neuropilin 
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VEGF family cytokines function by binding to VEGF receptor (VEGFR) tyrosine 
kinase and Neuropilin (Nrp) family members (Figure 1.2). In the human genome, 
there are three VEGFRs, named VEGFR-1,-2,-3, and two Nrp family members, 
which are Nrp 1 and 2. All 3 VEGFRs have 7 extracellular immunoglobulin-like 
(Ig) domains, a transmembrane domain and an intracellular portion containing a 
split kinase domain (12). Nrp family members are 130 KDa type I transmemebrane 
proteins with a short intracellular domain and five extracellular domains including: 
two complement binding CUB domains (a1 and a2), two coagulation factor 
domains (b1 and b2), and a Meprin/A5-protein/PTPmu (MAM) domain (c) (13, 14). 
VEGFR-2 and Nrp-1 are considered the major receptors for VEGF-A mediated 
angiogenesis. Indeed, VEGFR-2 and Nrp-1 knockout mice have similar vascular 
defects and embryonic lethality phenotype (15, 16). It is generally believed that 
VEGF-A signaling is delivered into the cell via VEGFR initiated tyrosine kinase 
cascade (17). Nrp enhances VEGF stimulated VEGFR-2 downstream tyrosine 
kinase signaling cascade and increases chemotactic activity when expressed 
together with VEGFR-2 in endothelial cells (18, 19). However, the specific role of 
Nrp and mechanism of Nrp function in this pathway are still not understood, 
although models have been proposed. 
 
Nrp independent signaling capacity 
It has been recently proposed that the vascular development defects seen in Nrp 
knockout are due to Nrp mediated independent signaling cascade, which works 
in parallel with VEGFR-2 signaling in angiogenesis (20). Interestingly, several 
studies indicate that Nrp-1 intracellular domain and synectin play a role in cell 
migration independent of VEGFR-2 (21-23), which agrees with this model. 
However, accumulating data from other groups do not support it. It has been 
reported that Porcine Aortic Endothelial (PAE) cells overexpressing Nrp itself do 
not respond to VEGF suggesting Nrp does not have independent signaling 
capacity (18). However, this negative result could be due to the possibility that 
PAE may not express the necessary downstream signaling molecules needed for 
Nrp-mediated signaling.  
Strikingly enough, it has been shown that the defective angiogenesis phenotype 
observed in Nrp null mouse embryos could largely be complemented by 
intraperitoneal injecting pregnant mice with Nrp ectodomain Fc fusion protein 
during early development, although this injection is not sufficient to rescue the 
embryonic lethality (24). Interestingly, it has been further demonstrated that 
transgenic mice with Nrp-1 lack of the intracellular domain are viable without the 
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vessel loss phenotype observed in Nrp-1 null mouse embryos, demonstrating 
that the membrane-anchored extracellular domain is largely able to compensate 
Nrp-1 loss (25). However, it was later determined that these mice have impaired 
arteriogenesis (26). As a result, it suggests that angiogenesis could largely 
proceed without the need of the Nrp intracellular domain mediated signaling, and 
Nrp intracellular domain is important for arteriogenesis but the mechanism is not 
very clear and still needs to be determined.  
 
The other Nrp ligand family: Class 3 semaphorins 
Class III Semaphorins (Sema3) are a family of seven secreted cytokines that 
play critical roles in Nrp/plexin mediated axon guidance during neural 
development (27) (Figure 1.1 and Figure 1.2). Indeed, axon guidance cues 
mediated by Sema3 family members are essential during development for 
correct neuronal patterning in dorsal root ganglia, facial, vagal, olfactory-sensory, 
cortical, hippocampal, and cerebellar nerves, along with others (28). Previous 
studies have shown that both Nrp and Plexin are required for correct neuronal 
patterning during early development (29-32). Sema3 regulates axonal patterning by 
binding to plexin family members and inhitiating axonal repulsive signal (29-32). 
Interestingly, Nrp has also been shown to be able to reverse Sema3-mediated 
axonal repulsion to attraction in certain cases (33, 34). 
All Sema3 members have the same overall domain architecture: a 500 amino 
acid Sema domain, a PSI domain, an Ig-like C2-type (immunoglobulin-like) 
domain, and a short C-terminal basic domain. A disulfide bond in a helical motif 
located in the c-terminal basic domain of Sema3 links two Sema3s into a dimer, 
and dimeric nature of Sema3 is essential for engaging two receptor molecules for 
signaling. The N-terminal a1 domain of Nrp-1 and Nrp-2 selectively binds the 
Sema domain of different Sema3 family members, which determines the 
specificity of ligand and receptor pairing (35-37).  Notably, Sema3A specifically 
signals via Nrp-1 (13, 14) and Sema3F via Nrp-2 (38). The Nrp b1 domain allows 
high-affinity non-selective binding to the Sema3 C-terminal domain (38-40).  
Following Sema3 binding by Nrp, Plexin family signaling receptors (PlexinA1-4) 
are then engaged and activated to directly guide axonal growth (30, 41).  Nrp 
functions by coupling specific high-affinity Sema3 binding to Plexin-dependent 
regulation of cytoskeleton dynamics in the axonal growth cone (30).   
Accumulating studies suggest that Sema3 is also an endogenous anti-angiogenic 
factor with unique roles under physiological and pathological conditions. For 
example, Sema3F forms a barrier that maintains the outer retina avascularity, 
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and Sema3E provides a guidance cue for retinal vascular pathfinding (42, 43). This 
Sema3 mediated anti-angiogenic activity was shown to result from PlexinD1 
signaling and downstream small GTPase RhoJ activation in endothelial cells. 
However, direct competition between the C-termini of Sema3 and VEGF-A for 
binding to Nrp b1 domain has been shown to be another mechanism for the anti-
angiogenic activity of Sema3 (40), emphasizing the importance of understanding 
the mechanism of Nrp ligand binding.  
 
VEGF and Sema3 competition and Nrp inhibitor design 
Indeed, intensive studies have been focused on illustrating the mechanisms of 
VEGF and Sema3 ligand and Nrp receptor interactions. It has been shown that 
VEGF-A binds to the first coagulation factor (b1) domain of Nrp, and mutation in 
this binding site generates a dominant negative angiogenesis inhibitor (44, 45). The 
C-terminal basic rich region of Sema3 mediates the high affinity Nrp interaction 
by binding to its coagulation factor domain (44), however, there had been a long 
debate about whether they bind to the same site competitively or distinct sites 
independently.  
Previous work in our laboratory provides evidence for the competitive nature of 
the interactions between these two ligands to Nrp. We have first demonstrated 
that all VEGF family members possess a C-terminal arginine, which is both 
necessary and sufficient for binding to Nrp-1 b1 domain. We have further shown 
that additional C-terminal residues of VEGF from both exon 7 and 8 contributes 
to Nrp-1 b1 domain binding (46). Interestingly, none of the 7 Sema3 family 
members has a C-terminal arginine. We have showed that the C-terminus of 
Sema3 is proteolytically processed by furin, which is required for producing a C-
terminal arginine to compete with the C-terminal arginine of VEGF for binding to 
the Nrp coagulation factor domain (40, 47).  
VEGF mediated angiogenesis is not only important during development and 
wound healing, it is also critical for tumor progression. As a result, intensive effort 
has been made for Nrp peptide inhibitor development and tumor targeting. For 
example, a phage display study identified a C-terminal arginine based peptide 
RPARPAR with a Kd=1.7 ±0.4uM (48). Others used microfluidic systems and 
discovered two additional peptides with comparable binding affinity to Nrp 
(GGKRPAR and RIGRPLR) (49). Moreover, cyclic tumor-homing peptide LyP-1 
CGNKRTRGC was shown to be able to penetrate tumor tissue (50). Interestingly, 
this peptide was further shown to be processed by tumor tissue to release the C-
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terminal arginine for Nrp binding, suggesting a similar C-terminal arginine based 
mechanism (51). 
Ligand-derived inhibitory peptide design has been employed as another 
promising approach for targeting Nrp. EG3287, derived from the C-terminal 
amino acid 138 to 165 of VEGF-A, was shown to inhibit VEGF-A binding to Nrp-1 
with an IC50=2uM (52, 53). A larger peptide derived from the C-terminal amino acid 
111 to 165 of VEGF-A has been shown to inhibit VEGF-A binding to Nrp-1 with 
an IC50 about 300nM (54). Finally, work from our lab identifies a peptide from the 
C-terminus of Sema3F, which potently inhibits VEGF-A binding to Nrp-1 with an 
IC50=45nM, but the mechanism of this potent inhibition was unknown (40).  
Moreover, a C-glycosyl scaffold functionalized with side chains of amino acids 
mimicking ATWLPPR peptide yields an inhibitor with the IC50=92uM against 
VEGF-A binding to Nrp-1 (55). Interestingly, D(LPR) synthesized with D-amino 
acids is shown to be resistant to protease degradation but retain similar inhibition 
potency compared to its L-amino acid counterpart (56), which represents an 
interesting approach for optimizing peptide based Nrp-1 inhibitors. Finally, a 
small molecule Nrp inhibitor EG00229 has been shown to inhibit tumor cell 
survival and migration especially when given in combination with 
chemotherapeutic reagents (57). 
To further improve the Nrp inhibition efficiency, some of the peptide inhibitors 
have been coupled with cytotoxic reagents. For example, Kawakami et al fused 
Sema3A-derived peptide with lytic-type peptide to enhance its biological effect 
(58), while others conjugated ATWLPPR peptide with photosensitizer (59, 60). The 
Arap and Pasqualini groups have also demonstrated that Nrp-targeting peptide 
and pro-apoptotic peptide conjugate (CGFYWLRSC-GG-D(KLAKLAK)2) inhibits 
leukemias and lymphomas in vitro (61). Since it has been shown that these 
peptide conjugates are degraded rapidly after in vivo injection (59, 62), further effort 
was made to delay degradation. For instance, a pseudopeptide conjugate has 
been shown to be able to improve the in vivo stability dramatically (63), however, 
the inhibitory effect of this conjugate on tumor progression remains to be 
determined.  
 
Summary 
The cardiovascular system is critical for the daily life of all vertebrates. VEGF and 
its receptors, VEGFRs and Nrps, play an essential role in regulating the 
formation and homeostasis of this organ system starting from early development 
throughout the entire adulthood. In this dissertation, the author mainly focused on 
7	  
	  
one of VEGF membrane receptors Nrp-1 and utilized a variety of cell biology, 
biochemical and biophysical techniques to determine the mechanism of ligand 
receptor interaction and receptor activation, which are two critical steps required 
to sense and integrate extracellular ligand signals and transmit them into the 
target cells. 
 
Note: Part of this chapter has been published and is reproduced here for 
completeness of the dissertation (64).  
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Figure 1.1: Cross-talk between Nrp ligands allows coordinated regulation of 
vascular and neuronal tissues. Both endothelial cells and neurons express Nrp 
which can respond to either VEGF or Sema3 family guidance cues. Regulation of 
competitive Nrp binding between different ligands allows for an additional level of 
dominant control of Nrp function. 
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Figure 1.2: Nrp function is essential for VEGF mediated angiogenesis and 
Sema3 dependent axon guidance.  Cooperative binding of VEGF by VEGFR and 
Nrp activates the angiogenic cascade necessary for developmental and 
homeostatic angiogenesis and also pathological signaling associated with 
tumorigenesis and other types of aberrant signaling. Engagement and activation 
of Nrp and Plexin family receptors is required for axon guidance signaling.	   
 
 
 
 
 
 
 
 
 
 
 
Copyright © Hou-Fu Guo 2014 
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CHAPTER TWO 
 
Mechanistic basis for the potent anti-angiogenic activity of semaphorin 3F 
 
Introduction 
Neuropilins (Nrps) are an essential cell surface receptor family (64).  They function 
with Vascular Endothelial Growth Factor Receptors (VEGFRs) in VEGF-
dependent angiogenesis and with Plexin receptors in Sema3-dependent axon 
guidance (65-69).  In addition to their function in neurons, a critical role for specific 
Sema3 family members in physiological and pathological regulation of the 
cardiovascular system has been increasingly recognized (70-72).  For example, 
Sema3F is critical for maintaining an avascular outer retina, while Sema3A and 
Sema3E have important roles in vascular patterning (42, 43, 72, 73). In contrast, 
mutation and down-regulation of Sema3 family members is also observed in 
many types of solid tumors and has been directly correlated with tumor 
angiogenesis and cancer progression (70, 74, 75). Indeed, restoring the expression 
of Sema3B and Sema3F in tumors inhibits tumor cell proliferation in vitro and 
further cancer progression in vivo (76-79). 
Nrp serves a central role in integrating the opposing signals of VEGF and Sema3 
in both physiological and pathological contexts through competitive ligand 
binding.  The Nrp-1 b1 coagulation factor domain has a conserved C-terminal 
arginine binding pocket that is critical for competitive VEGF and Sema3 binding 
(40, 47).  Alternative splicing of VEGF-A regulates Nrp-1 binding (80), with the exon 
eight encoded C-terminal arginine residue being necessary for binding Nrp-1-b1 
(46).  In contrast, furin proteolysis of Sema3 is critical for regulating its ability to 
bind Nrp and function.  Furin processing can either inactivate or activate Sema3 
by processing at sites in the central or C-terminal domains, respectively.  
Processing in the central region of Sema3 has been primarily reported to 
inactivate Sema3 activity by cleaving the protein into two fragments, although the 
fragments may still possess activity (81-83). Furin processing within the Sema3 C-
terminal domain is critical to activate the Sema3 pro-protein by producing a C-
terminal arginine, allowing competitive engagement of Nrp-1-b1 (40, 84).  
Multiple C-terminal arginine containing peptides and peptido-mimetics have been 
produced as competitive antagonists of VEGF-A/Nrp-1 binding (48, 85, 86).  While 
functioning as inhibitors in vitro and in situ, these peptides and peptidomimetics 
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suffers from limited potency (IC50≈10-50 µM). In contrast, endogenous Sema3F 
functions as a potent inhibitor of VEGF-A binding to Nrp-1 (40).  However, the 
molecular mechanism of high-affinity Sema3F binding to Nrp-1 has not been 
elucidated, leaving open the question of how Sema3F potently competes for Nrp-
1 binding. 
In the present study, we demonstrate the mechanistic basis for the potency of the 
furin-processed C-terminal domain of Sema3F (C-furSema) (Figure 2.1A) in vitro 
and in situ. We find that C-furSema exhibits unique hetero-bivalent engagement 
and that this bivalent binding is essential for high affinity Nrp-1 binding.   
 
Methods 
C-furSema and Variant Production 
Homodimeric C-furSema (GLIHQYCQGYWRHVPPSPREAPGAPRSPEPDQK 
KPRNRR), truncations, and point mutants were synthesized using solid phase 
synthesis, oxidized to produce the natural intermolecular disulfide, and purified 
with reversed phase high-performance liquid chromatography (HPLC) using 
4.6mm*250mm, SinoChrom ODS-BP column to >95% purity (Neo-Peptide, 
Cambridge, MA). The monomeric C-furSemaMon 
(GLIHQYSQGYWRHVPPSPREAPGAPRSPEPDQKKPRNRR) was produced in 
the same manner without oxidization. C-furSemaHet was produced by combining 
separately synthesized reduced C-furSema and C-furSemaHelix 
(GLIHQYCQGYWRH), oxidized in the presence of the excess C-furSemaHelix, 
and purified with reversed phase HPLC using 4.6mm*250mm, SinoChrom ODS-
BP column to >95% purity (LifeTein, South Plainfield, NJ).  All C-furSema 
variants were well behaved in solution and soluble to >1 mM.  A dimeric 
construct of C-furSemaHelix alone showed limited solubility, with a maximal 
solubility in Phosphate Buffered Saline (PBS) of 20 µM, and no ability to inhibit 
VEGF-A binding up to the limit of solubility.   
Protein and peptide concentrations were determined using OD280 measured on a 
Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, DE).  
 
In situ inhibition assays 
Porcine aortic endothelial (PAE) cells stably overexpressing VEGFR-2 and Nrp-1 
were utilized to measure the ability of C-furSema to block VEGF-A activation of 
VEGFR-2 (87). PAE cells were grown in F12 medium (Invitrogen, Grand Island, 
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NY) supplemented with 10% Fetal Bovine Serum (FBS) (Invitrogen, Grand 
Island, NY) and 1% Pen/Strep in 6-well cell culture plates to 70% confluence. 
Cells were then serum starved for 16 hours in Endothelial Cell Basal Growth 
Medium-2 (EBM-2) (Lonza, Walkersville, MD). C-furSema samples were 
resuspended in EBM-2, added at a final concentration of 10 mM, and incubated 
for 90 minutes at 37°C.  Cells were then stimulated with 100 ng/ml VEGF-A (R&D 
Systems, Minneapolis, MN) for 3 minutes. After 3 minutes, media was removed 
and cells solubilized in RIPA buffer supplemented with phosphatase and 
protease inhibitor (Roche, Germany).  Total VEGFR-2 and VEGFR-2 
phosphorylation was determined by western blotting using 55B11 and 19A10 
antibodies (Cell Signaling, Danvers, MA), respectively, at a 1:1000 dilution 
followed by goat anti-rabbit HorseRadish Peroxidase (HRP) conjugated 
secondary antibody at 1:20000 dilution (sc-2301, Santa Cruz).  The SuperSignal 
West Femto chemiluminescence (ECL) detection system (Thermo Fisher 
Scientific, Rockford, IL) was used for detection of immunoreactivity on X-ray films 
(HyBlot CL; Denville Scientific, Inc. Metuchen, NJ). Experiments were performed 
in triplicate and results reported as the mean ± 1 standard deviation. 
For determination of in situ potency, a VEGFR-2 cellular phosphorylation 
sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA) was utilized 
(ProQinase, Germany).  Primary Human Umbilical Vein Endothelial Cells 
(HUVECs) were plated in Endothelial Cell Growth Medium (ECGM) 
supplemented with 10% FBS (PromoCell, Germany), serum starved for 16 hours, 
incubated with varying concentration of C-furSema for 90 minutes, and then 
activated with VEGF-A at 100ng/ml for 3 minutes. The level of VEGFR-2 
phosphorylation was determined via sandwich ELISA using a VEGFR-2 capture 
antibody and anti-phosphotyrosine detection antibody (PromoCell, Germany). 
Raw data were converted into percent phosphorylation relative to high and low 
controls. Cells treated with VEGF-A alone were defined as high control (100%), 
and those treated with 1 µM sunitinib, a well characterized VEGFR-2 kinase 
inhibitor with an IC50=10nM, were defined as low control (0%).  Inhibition curves 
were fit using a standard four-parameter sigmoidal curve to yield the IC50.   
Experiments were performed in duplicate and results reported as the mean ± 1 
standard deviation.  
 
Protein expression and purification 
Proteins were expressed and purified using established protocols (40).  Briefly, 
Nrp-1-b1b2 (residue 274 to 586) was expressed in E. coli and purified using 
nickel affinity chromatography (IMAC) followed by heparin affinity 
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chromatography.  Alkaline Phosphatase (AP) fused VEGF-A was produced from 
Chinese Hamster Ovary (CHO) cells. 
 
In vitro inhibition assays 
Plate-based inhibition assays were performed as previously reported (40).  Briefly, 
AP-VEGF-A (410 µM para-nitrophenol phosphate (p-NPP) hydrolyzed/min/µL) 
was combined with Sema3F-derived peptides in binding buffer (20 mM Tris, pH 
7.5/50 mM NaCl), incubated with Nrp-1 affinity plates for 1 hour at 25°C, washed 
three times with PBS-T (0.01M Phosphate buffered saline, 0.1% Tween 20, pH 
7.4), incubated with PBS-T for 5 minutes, aspirated, and developed by addition of 
100µL of 1X alkaline phosphatase pNPP substrate (88) followed by quenching 
with 100µL of 0.5N NaOH. AP activity was quantitatively measured at 405nm 
using a SpectraMax M5 instrument (Molecular Devices, Sunnyvale, CA).  Binding 
curves were fit using a standard four-parameter sigmoidal curve to yield the IC50. 
Inhibitory potency is expressed per-subunit for peptides to allow direct 
comparison between dimeric and monomeric peptides. Experiments were 
performed in triplicate and results reported as the mean ± 1 standard deviation.  
An unpaired t-test was used to compare IC50 values. 
 
Thermodynamic Calculations 
Since VEGF-A and C-furSema are dimeric ligands, the interaction between Nrp-1 
b1b2 and VEGF-A/ C-furSema follows the following equation.  
VEGF-A/ C-furSema + 2 Nrp-1 b1b2 = VEGF-A/ C-furSema (Nrp-1 b1b2)2 
Since VEGF-A and Sema3 receptor Nrp-1 b1b2 is immobilized onto the plate, the 
equation can be simplified into the following form. 
VEGF-A/ C-furSema + Nrp-1 b1b2-Nrp-1 b1b2 = VEGF-A/ C-furSema Nrp-1 
b1b2-Nrp-1 b1b2 
In this equation, we assume that two copies of Nrp-1 b1b2 (Nrp-1 b1b2-Nrp-1 
b1b2) are engaged by ligands simultaneously. Since the dissociation constant Kd 
of VEGF-A Nrp-1 b1b2 complex in our plate based binding assay is 3 nM 
(Matthew Parker personal communication), IC50 values of C-furSema, 
truncations, and point mutants were then converted into inhibitor dissociation 
constant Ki using Cheng-Prusoff equation.  
Ki = IC50/(1+[Ligand]/Kd) 
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Where [ligand] is the concentration of AP-VEGF-A used in the plate based 
inhibition assay, which is 2.83 nM.  
The inhibitor and Nrp-1 interaction free energy ΔG was then calculated from 
inhibitor dissociation constant Ki using the following equation. 
ΔG = - RTlnKi 
Where R = gas constant and T = absolute temperature.  
 
Circular Dichroism (CD) 
C-furSema and C-furSemaMon were dissolved in 0.01M sodium phosphate 50mM 
NaCl, pH=6.5 at a concentration of 0.5mg/ml. CD spectra were measured using a 
J-810 spectrapolarimeter (Jasco, Easton, MD) with a 1 mm path length quartz 
cuvette. All measurements were performed at 25°C and three scans averaged for 
each spectrum. A blank spectrum was collected in the same manner and used 
for background subtraction. The fraction of secondary structure was determined 
by K2D3 using the wavelength range from 200nm to 240nm (89). 
 
Results 
C-furSema is a potent inhibitor in situ  
To determine the potency of C-furSema function in cellular context, we examined 
its ability to inhibit VEGF-A mediated activation of VEGFR-2.  Nrp-1 and VEGFR-
2 were stably expressed in PAE cells (87), and the ability of C-furSema to inhibit 
VEGF-A dependent phosphorylation of VEGFR-2 Y1175 was assessed.  C-
furSema markedly inhibited VEGF-A dependent VEGFR-2 activation (Figure 
2.1B).  To confirm this finding in a distinct cell type, and determine the potency 
and extent of this inhibition in primary endothelial cells, we measured the dose-
dependent inhibitory effect of C-furSema on the activation of VEGFR-2 in 
HUVEC cells using a quantitative sandwich ELISA.  Strikingly, C-furSema 
showed potent inhibition of VEGFR-2 activation with an IC50=34 ± 15 nM (Figure 
2.1C), consistent with its potency in vitro (40), and more than two orders of 
magnitude greater than short peptide inhibitors of Nrp-1 (57, 85, 86, 90).  Additionally, 
complete inhibition of VEGFR-2 activation was observed in HUVEC cells, in 
contrast to other Nrp inhibitors that are able to only partially inhibit VEGFR-2 
activation even at maximal dose (86).  Thus, C-furSema is a potent inhibitor of 
Nrp-1-dependent activation of endothelial cells in situ. 
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Mechanism of C-furSema potency 
C-furSema, which corresponds to the full C-terminal basic domain of Sema3F, is 
larger and more complex than peptide and peptido-mimetic inhibitors that have 
been developed to target Nrp-1.  Given the dimeric nature of C-furSema, due to 
its conserved inter-molecular disulfide bond, we predicted that the potency of C-
furSema might be attributable to avidity effects arising from dual engagement of 
Nrp-1. Indeed, previous studies have demonstrated that oligomeric peptide 
inhibitors of Nrp have enhanced potency (86).  
To test this, we produced a monomeric form of C-furSema by mutating the single 
conserved cysteine residue responsible for dimerization to serine (C-
furSemaMon). The ability of C-furSema and C-furSemaMon to competitively block 
VEGF-A binding to Nrp-1 was compared (Figure 2.2). A significant decrease in 
potency was observed for the monomer (black line, IC50 = 1.3 ± 0.7 µM) 
compared to the dimer (grey line, IC50 = 24 ± 1 nM).  The monomer has a 9.7 ± 
2.7 KJ mol-1 decrease in binding free energy compared to dimer. While these 
data indicate a direct correlation of oligomerization and potency, it is notable that 
the monomeric species of C-furSema is still an order of magnitude more potent 
than previously published inhibitors (57, 85, 86, 90), suggesting that additional 
mechanisms may contribute to C-furSema potency. 
A C-terminal arginine has been shown to be critical for Nrp ligand binding (47).  In 
the Sema3 family, furin processing liberates a C-terminal arginine and is required 
for Nrp binding (40, 84).  In Nrp-1 ligands, residues near the C-terminal arginine 
have been shown to contribute to potency and selectivity (46).  Thus, we 
hypothesized that residues directly upstream of the C-terminus might be 
responsible for enhanced potency.  
To test the role of the C-terminal residues, we performed alanine scanning 
mutagenesis of the seven C-terminal residues of C-furSema (Figure 2.3A & B). 
As expected, mutation of the C-terminal arginine of C-furSema to alanine, 
R779A, dramatically decreased its inhibition potency by greater than two orders-
of-magnitude (IC50 = 4.5 ± 0.2 mM).  Surprisingly, no other mutation decreased 
C-furSema potency. In fact, the R778A was slightly more potent, consistent with 
a recent report of a role for the C-1 position in tuning potency (91).  These data 
confirm the importance of a C-terminal arginine in Sema3 binding to Nrp-1, but 
indicate that the residues directly upstream minimally contribute to potent 
competitive binding to Nrp-1.  Therefore, the enhanced potency of C-furSema 
16	  
	  
relative to other peptide inhibitors cannot be explained by additional interactions 
within the region directly proximal to the C-terminal arginine.  
 
Contribution of the N-terminal helical region 
In addition to the C-terminus, the N-terminal sequence of C-furSema is 
conserved across species.  Furthermore, secondary structure predictions 
indicate a-helical propensity for the eleven amino acids centered around the 
cysteine (Figure 2.4A).  Notably, this is the only predicted structured region in the 
otherwise extended C-terminal basic domain of Sema3.  Based on this, we 
hypothesized that the N-terminus may be involved in binding to Nrp-1.  To test 
this, we produced a protein with half of the predicted helix deleted but which 
retained the conserved cysteine residue necessary and sufficient for dimerization 
(DN-C-furSema). Based on a simple avidity model, DN-C-furSema should have 
unaltered inhibitory potency.  Strikingly, DN-C-furSema was approximately five-
fold less potent than C-furSema (IC50 = 111 ± 21 nM and 25 ± 3 nM, respectively) 
(Figure 2.4B).  This means that DN-C-furSema has 3.6 ± 0.6 KJ mol-1 decrease 
in binding free energy compared to C-furSema. These data suggest that the N-
terminal region of C-furSema, centered around the conserved cysteine, 
contributes to potent competitive inhibition of VEGF-A binding to Nrp-1.  
However, this could be due to either direct binding of the N-terminal region to 
Nrp-1 or indirect effects of orienting the two C-terminal arginines for optimal Nrp 
binding. 
The conserved cysteine of C-furSema is required both for oligomerization and 
potent competitive Nrp-1 binding.  Interestingly, the cysteine is centered within 
the predicted N-terminal helix.  This led us to examine the possibility of an 
additional role for the intermolecular disulfide in maintaining the structure of the 
N-terminal region.  Thus, we compared the secondary structure of C-furSema 
and C-furSemaMon using CD.  The overall spectra are consistent with the 
predicted secondary structure of C-furSema, an overall coil with a smaller helical 
component.  The difference spectrum clearly shows a loss of helical character in 
C-furSemaMon (Figure 2.4C).  Fitting the individual spectra reveals an 
approximately 30% loss in helicity in C-furSemaMon, with 16% overall helical 
composition for C-furSema compared to 11% for C-furSemaMon.  These data 
indicate that the conserved cysteine that forms the key intermolecular disulfide in 
Sema3F is not only important for determining the oligomeric state of C-furSema 
but also in stabilizing the N-terminal helical region of C-furSema required for 
potent engagement of Nrp-1.  
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We interpret these data to indicate that the disulfide stabilized N-terminal helix 
directly contributes to Nrp-1 binding.  However, it remains possible that this 
region indirectly affects potency by imposing conformational constraints that 
orient the C-furSema dimer.  To distinguish between these possibilities, we 
designed a heterodimer composed of one subunit of C-furSema and one subunit 
containing only the thirteen N-terminal helical residues (C-furSemaHet) (Figure 
2.5A).  This construct contains the full N-terminal helix but only a single C-
terminal arginine.  This unique disulfide linked heterodimer was produced and 
purified to >95% purity (Figure 2.5B).  Strikingly, C-furSemaHet was as potent as 
C-furSema at inhibiting VEGF-A-dependent activation of endothelial cells (Figure 
2.5C) and VEGF-A binding to Nrp-1 (Figure 2.5D, IC50 = 35 ± 3 nM and 24 ± 1 
nM, respectively). This is in stark contrast to C-furSemaMon, with an IC50 = 1.3 ± 
0.7 mM (Figure 2.5D).  These data emphasize the importance of the N-terminal 
helical region and demonstrate that C-furSema potency is determined by a 
hetero-bivalent mechanism combining a C-terminal arginine and structured N-
terminal helical region. 
 
Discussion 
Together, these data demonstrate that Sema3 family members engage Nrp-1 
utilizing two distinct regions in their C-terminal domain, a C-terminal arginine and 
upstream helical region (Figure 2.6).  This engagement results in potent 
competitive binding to Nrp-1 that antagonizes VEGF binding and cellular 
activation. Importantly, the decreased potency observed between dimeric and 
monomeric forms of C-furSema is primarily due not to the presence of two C-
terminal arginine motifs, but instead the presence of the stable helical motif, as 
demonstrated by the potency of C-furSemaHet.  These data indicate that the 
potent competitive binding of C-furSema to Nrp-1 is determined by a unique 
hetero-bivalent mechanism requiring only one C-terminal arginine and the novel 
upstream helical region.   
Previously, it has been shown that the exon seven encoded residues of VEGF-A 
engage the L1 loop of the Nrp-1 b1 domain, enhancing binding and controlling 
Nrp-1 receptor selectivity (46).  In contrast, the L1 loop of Nrp-1/2 does not play a 
role in selective Sema3 binding (92).  Our current data demonstrate that Sema3s 
utilize its upstream helical motif to enable potent hetero-bivalent engagement of 
Nrp.  The physical location of the Sema3 helical binding site on Nrp-1 is an 
important future direction for both mechanistic insights into Sema3 function and 
inhibitor design.   
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Since Nrp has critical roles in pathological angiogenesis and aberrant axon 
guidance, significant effort has been devoted to producing Nrp inhibitors.  
Peptide and small molecule inhibitors have been produced against the C-terminal 
arginine binding pocket, but generally possess modest (µM) potency (57, 86, 90, 93). 
We demonstrate that by coupling inhibitor oligomerization with covalent tethering 
of the helical and C-terminal arginine binding motif, a two order-of-magnitude 
gain in inhibitory potency can be achieved.  The identification of two distinct Nrp-
1 binding sites that, when tethered together, produce a potent inhibitor presents 
exciting possibilities for fragment-based design strategies combining existing 
inhibitors of the C-terminal arginine binding pocket with novel helical motif 
binding site inhibitors.   
The physiological role of furin processing in the regulation of Sema3 signaling, as 
opposed to inhibition of VEGF binding, remains to be determined.  While 
inhibition only requires avid binding to a single Nrp receptor, Sema3 signaling 
minimally requires engagement of two receptor molecules and assembly of the 
signaling complex.  Our data indicate that, at a minimum, furin processing is 
required to activate Sema3 for Nrp b1-domain binding by liberation of a C-
terminal arginine. Importantly, C-furSemaHet maintains potent engagement of 
Nrp, suggesting that furin processing of a single subunit of the Sema3 dimer may 
be sufficient for potent activation.  Alternatively, furin processing may effect 
Sema3 engagement of the Nrp b1 domain quantitatively such that the different 
forms have progressively increasing signal potency from unprocessed to singly 
processed to dual processed. 
Sema3 engagement of Nrp is more complex than VEGF in that two distinct 
domains are required.  Both Sema3 C-terminal domain binding to the Nrp b1 
domain and Sema3 Sema domain binding to the Nrp a1 domain are important for 
Sema3 signaling (36, 44).  Recent structural work has provided significant insight 
into the contribution of the Nrp a1 domain in Sema3 binding (94) and assembly of 
the active Sema3/Plexin/Nrp complex (95).  The specific contribution of a1 and b1 
domains in terms of binding potency, specificity, and coupling between the two 
interacting domains is an active area of research (69). 
The ability of Sema3 to engage the Nrp b1-domain has clear implications for 
Sema3 signaling in the nervous system but also in the cardiovascular systems. 
For example Sema3A, which is critical for nervous system development (27), has 
been shown to inhibit VEGF-dependent angiogenesis, yet acts as a vascular 
permeability factor (73).  Inhibition of VEGF is consistent with our data 
demonstrating direct competition for Nrp binding.  However, induction of vascular 
permeability by Sema3 was found to be due to specific Nrp-dependent signaling 
rather than competitive binding.  It is possible that these two functions of Sema3 
19	  
	  
in the cardiovascular systems are differentially regulated by furin processing. 
Indeed, furin processing of Sema3 family members may have significant 
physiological implications for regulated function in both nervous and 
cardiovascular systems (64). 
Note: Part of this chapter has been published and is reproduced here for 
completeness of the dissertation (96). 
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Figure 2.1: C-furSema potently inhibits VEGF-A mediated VEGFR-2 activation in 
situ.  A) A schematic representation of Sema3 highlighting the furin-processed C-
terminal domain (C-furSema). B) Activation of PAE cells stably overexpressing 
Nrp-1 and VEGFR-2 by VEGF-A is inhibited by C-furSema as demonstrated by a 
decrease in VEGFR-2 Tyr-1175 auto-phosphorylation.  C) C-furSema is a potent 
dose-dependent inhibitor of VEGF-A mediated HUVEC activation as 
demonstrated by sandwich ELISA (IC50 = 34 ± 15 nM). Phospho-VEGFR-2 levels 
were normalized to VEGF-A alone and 1 µM sunitinib. 
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Figure 2.2: Effect of the intermolecular disulfide on C-furSema potency. A) 
Comparison of dimeric C-furSema and C-furSemaMon B) reveals a critical role for 
the conserved inter-molecular disulfide C-furSema (grey line, IC50 = 24 ± 1 nM) 
and C-furSemaMon (black line, IC50 = 1.3 ± 0.7 mM) in inhibiting VEGF-A binding 
to Nrp-1.   
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Figure 2.3: C-furSema C-terminal arginine contributes to high affinity binding to 
Nrp. A) An alanine scan of the C-terminus of C-furSema was performed. The 
ability of C-furSema and mutants to inhibit AP-VEGF-A binding to Nrp-1 was 
determined.  B) Inhibition curves were utilized to determine peptide potency 
(IC50), with a significant decrease only observed with the C-terminal arginine 
mutant. 
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Figure 2.4: The N-terminal helical motif is a structured region that contributes to 
potency. A) Sequence, predicted secondary structure, and conservation of C-
furSema (based on an alignment of human, rat, mouse, cow, dog, chicken, and 
zebrafish orthologs).  B) DN-C-furSema, a N-terminal helical deletion decreases 
the potency of C-furSema (IC50 = 111 ± 21 nM vs. 25 ± 3 nM, respectively).  C) 
Difference CD spectrum of dimeric versus monomeric C-furSema reveals a 
characteristic loss in α-helical content. (Inset) CD spectra of dimeric C-furSema 
(dashed line) and C-furSema3Mon (solid line).  
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Figure 2.5: The helical motif determines potent competitive Nrp-1 binding.   
A) To determine the contribution of N-terminal helical region in mediating Nrp 
inhibition, C-furSemaHet was synthesized. B) Comparison of non-reducing versus 
reducing SDS-PAGE demonstrates the purity and correct intermolecular disulfide 
bond formation of C-furSema and C-furSemaHet. C) C-furSema and C-furSemaHet 
equivalently inhibit VEGF-A dependent activation of PAE cells and D) have 
nearly equal potencies, IC50 = 24 ± 1 nM vs. IC50 = 35 ± 3 nM, respectively. 
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Figure 2.6: Sema3 family members engage Nrp-1 utilizing two distinct regions in 
their C-terminal domain, a C-terminal arginine and upstream helical region.  This 
divalent synergistic engagement results in potent competitive binding to Nrp-1 
that antagonizes VEGF mediated angiogenesis. 
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CHAPTER THREE 
 
Semaphorin 3F anti-angiogenic activity regulation 
 
Introduction 
Sema3 is a family of secreted cytokines with seven family members playing 
essential roles in Nrp-plexin mediated axon guidance (27). Biochemical and 
animal studies have shown that both Nrp and Plexin are essential for correct 
neuronal patterning during early development largely by delivering axonal 
repulsive signal (29-32). However, interestingly, Nrp expression in certain neurons 
has also been demonstrated to be able to change their interpretation of Sema3 
signal from axonal repulsion to attraction (33, 34). 
Recent studies have shown that Sema3 also plays anti-angiogenic roles under 
physiological and pathological conditions. For instance, Sema3F expression in 
outer retina is critical for maintaining this part of retina avascular, and Sema3E 
serves as a guidance cue for retina vasculature (42, 43). Studies have also shown 
that Sema3 family members are mutated or down-regulated in many cancers, 
including lung, ovary, stomach, breast, and prostate cancers (70, 74, 75). Restoring 
the expression of Sema3B and Sema3F has been reported to inhibit cancer 
progression both in vitro and in vivo (76).  
All Sema3 family members are disulfide-bonded homo-dimers with 4 domains 
including, a 500 amino acid Sema domain, a PSI domain, an Ig-like C2-type 
(immunoglobulin-like) domain, and a short C-terminal basic domain. A single 
disulfide bond links the molecule into a dimer and is located in the helical motif 
from the c-terminal basic domain of Sema3, which is critical for Sema3 to interact 
with two receptor molecules for signaling.  
Since Sema3 serves critical roles in Nrp-mediated axon guidance and 
angiogenesis, intensive effort have been made to define the mechanisms of 
ligand and receptor interactions. Sema3 functions by binding to Nrp using two 
different regions, the Sema domain and the C-terminal basic rich region (13). The 
Sema domain of Sema3 family members binds to the CUB domain of Nrp and 
this interaction determines the specificity of the ligand/receptor pairing (36, 44, 94). 
The C-terminal basic rich region of Sema3 mediates the high affinity Nrp 
interaction by binding to its coagulation factor domain b1 (44). Interestingly, it has 
been demonstrated VEGF also binds to Nrp b1 domain, just as Sema3, and they 
compete for Nrp binding (40). 
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Since it has been shown that the anti-angiogenic role of Sema3 is to physically 
compete with VEGF for Nrp binding (40), the interaction between the Sema3 C-
terminal basic domain and Nrp b1 domain is important for not only engaging Nrp 
in plexin mediated axonal guidance, but also in Sema3 mediated anti-angiogenic 
activities. Structural studies have shown that the Nrp b1 domain has a C-terminal 
arginine-binding pocket and is able to bind to ligands with a C-terminal arginine 
(47). Indeed, it has been shown that the interaction between VEGF-A and the first 
coagulation factor (b1) domain of Nrp is largely mediated by VEGF-A C-terminal 
arginine (46, 47). The mechanism is widely used by four other VEGF family 
members, VEGF-B, -C, -D and PlGF to interact with two Nrp family members, 
Nrp-1 and Nrp-2. We and other groups have previously shown that the C-
terminus of Sema3 is proteolytically processed by furin, which releases a C-
terminal arginine and is required for competing with VEGF-A for binding to the 
Nrp b1 domain (40).  
Interestingly, we have also shown that, besides the C-terminal arginine motif, a 
conserved helical motif in the C-terminal basic domain of Sema3F is required for 
high affinity binding to Nrp b1 domain as shown in chapter 3 and (97). Indeed, 
covalent tethering of this predicted helical binding motif leads to synergistic 
binding to Nrp, and two orders of magnitude better in binding affinity compared to 
the other C-terminal arginine based modalities (57, 85, 86, 90).  Interestingly, the 
helical motif is conserved in all Sema3 family members, suggesting this tethering 
mode is widely utilized in Sema3 for high affinity Nrp binding.  
We have also shown that it is the helical nature of this motif that is critical for Nrp 
binding (97). Indeed, a mutation destabilizing the helical nature of this motif results 
in near two orders of magnitude loss in binding affinity. In order to determine its 
helical nature and directly visualize this helix, we have determined the crystal 
structure of this motif. Our structure showed that indeed this structure is a 
versatile helix. An intermolecular disulfide bond and further molecular interactions 
hold two copies of helical motifs into a dimer, which stabilizes the helical 
structure. Further, It is notable that Sema3A possesses three furin processing 
sites between the helical region and the C-terminal arginine, and different C-
terminal furin processed Sema3A isoforms show a range of potencies, which 
correlates with the distance between the helical and C-terminal arginine binding 
motifs. 
 
Methods 
Protein expression and purification 
28	  
	  
Proteins used in plate binding assay were expressed and purified using the 
similar method as reported before (40). Briefly, rat Nrp-1 coagulation (b1) domain 
(residue 274 to 429) and human Sema3F helical motif (residue 740 to 752) 
fusion construct was cloned into pET-28 vector using the Nde1 and EcoR1 sites, 
expressed in E. coli, and purified using IMAC nickel-charged resin. The protein 
was then left in the presence of thrombin on the nickel resin for 16 hours at 20°C 
to remove the His tag and facilitate intermolecular disulfide bond formation at the 
same time. The dimer is then purified by heparin affinity chromatography and 
eluted at 600 mM NaCl in Tris pH 8.0. Nrp-1-b1b2 (residue 274 to 586) and Nrp-
2-b1b2 (residue 276 to 597) was expressed in E. coli and purified using nickel 
affinity chromatography (IMAC) followed by heparin affinity chromatography.  
Alkaline Phosphatase (AP) fused VEGF-A or VEGF-C was produced from 
Chinese Hamster Ovary (CHO) cells as discussed in chapter 2. 
 
Crystal Structure Determination and Refinement 
Single, high-quality crystals with 2 dimer molecules in the asymmetric unit were 
obtained via hanging drop vapor diffusion using a Mosquito liquid handling robot 
(TTPLabtech) using a 200-nL drop with Nrp-1 b1b2-Sema3F helix fusion protein 
(4.8 mg/mL) in 3 M formate, 100mM HEPES pH 7.5 at 20°C. Diffraction data 
were collected on the 22-ID beamline of SERCAT at the Advanced Photon 
Source, Argonne National Laboratory (Table 3.1) at 110K at a wavelength of 1.0 
Å. Data were processed using HKL2000 (98). The b1 domain of a previously 
published rat Nrp-1 b1b2 domain was used as a search model for molecular 
replacement using CCP4i (47). The structures were then fully built and refined via 
iterative model building and refinement using Coot (99) and Refmac5 (100), 
respectively. Stereochemistry of the model was analyzed using Mol-Probity (101). 
Molecular graphics were prepared using Pymol (102).  
 
C-furSema, Sema3A and Variant Production 
C-furSema (GLIHQYCQGYWRHVPPSPREAPGAPRSPEPDQKKPRNRR) and 
homodimeric peptide derived from a furin processed form of Sema3A C-terminus 
(LNTMDEFCEQVWKRDRKQRRQRPGHTPGNSNKWKHLQENKKGRNRRTHEF
ERAPR), and other furin processed shorter isoforms, were synthesized and 
purified in the same way as discussed in chapter 2 (Neo-Peptide, Cambridge, 
MA). C-furSema and all Sema3A C-terminus derived peptides were well behaved 
in solution and soluble to >1 mM.  
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Protein and peptide concentrations were determined using OD280 measured on a 
Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, DE).  
 
In vitro inhibition assays 
Plate-based inhibition assays were performed as discussed in chapter 2 and 
previously reported (40).  Briefly, 410 µM para-nitrophenol phosphate (p-NPP) 
hydrolyzed/min/µL of AP-VEGF-A or 5.0 mM para-nitrophenol phosphate (p-
NPP) hydrolyzed/min/µL of AP-VEGF-C was combined with C-furSema or 
Sema3A-derived peptides in binding buffer (20 mM Tris, pH 7.5/50 mM NaCl), 
incubated with Nrp-1 or Nrp-2 affinity plates for 1 hour at 25°C. The plates were 
then washed and developed in the same way as described in chapter 2. 
Experiments were performed in triplicate and results reported as the mean ± 1 
standard deviation.  An unpaired t-test was used to compare IC50 values. 
 
Results 
Structure determination and the model 
Since the Sema3F helical motif of the c-terminal basic domain has limited 
solubility, with a maximal solubility in Phosphate Buffered Saline (PBS) of 20 µM, 
a construct of this motif fused to the C-terminus of its receptor Nrp-1 b1 domain 
was designed with a Val-Asp linker between them. The recombinant protein was 
expressed and purified as stable soluble protein for crystal trials. The diffraction 
data were collected at 2.6 Å, and the structure was determined by the molecular-
replacement method using rat Nrp-1 b1 domain as a searching model (47). The 
Sema3F helical motif was manually built with coot (99) and refined using refmac5 
(100) to generate the final model (Table 3.1). 
The final refined model has 2 dimer molecules in the asymmetric unit (Figure 
3.1). Each monomer molecule has 171 of the 175 residues built into the final 
refined model. The N-terminal residues (Gly-Ser-His-Met) are part of the 
thrombin digestion site and restriction enzyme site for cloning, and the electron 
density for these residues are not clear defined and thus are not included in this 
model. The rest of the structure including the Sema3F helical motif has well 
determined electron density and is fully built. This model thus has 684 residues 
total together with 251 water molecules. 
In each of the 4 recombinant protein monomers, the predicted Sema3F helical 
motif indeed adopts a α-helical secondary structure, which is consistent with 
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previous circular dichroism results (97). Importantly, the Sema3F helical domain 
extends out from the C-terminus of Nrp-1 b1 domain, and does not make contact 
with the Nrp-1 b1 domain that it is fused with (Figure 3.2). 
A disulfide bond links Sema3F helical monomers together into a dimer, which is 
known to be critical for Sema3 activity (Figure 3.3A). This helical dimer is further 
stabilized by other interactions. Interstingly, these two monomers are different in 
helical content, one of which is highly helical while the other one is only partially 
helical in nature. The I434 residue from the monomer molecule with high helical 
content forms a hydrophobic interaction with the ring of Y437 in the other partial 
helical monomer (Figure 3.3B). The rings from Y441 and W442 residues from the 
same full helical monomer together with I434 from the other partial helical 
monomer form a hydrophobic niche for the disulfide bond. These features are 
consistent in the other molecule in the asymmetric unit. 
Within the Sema3F helical motif dimer, two monomer molecules adopt different 
conformations especially in the residues located to the C-terminus of this motif 
after the disulfide bond (Figure 3.3A). In one molecule, a continuous helix is 
present from N-terminus to C-terminus of this motif, with a kink present at the site 
of disulfide bond. In the other monomer molecule, a similar kink at the site of 
disulfide bond is also observed, however, the residues located to the C-terminus 
of this motif after the disulfide bond adopts a loop conformation and folds back to 
the helical structure. This indicates that this part of the structure is labile and is 
able to adopt multiple confirmations.  
 
C-furSema servers as a pan-Nrp inhibitor 
Besides the first member of the VEGF ligand family, VEGF-A, vertebrates also 
have four other VEGF family members, named VEGF-B,-C,-D, and placental 
growth factor (PlGF) (10).  The different family members utilize different Nrp family 
members and play both unique and partially overlapping in vivo roles in the 
vascular system.  Angiogenesis is mainly regulated by VEGF-A and Nrp-1 
interaction, whereas lymphangiogenesis is largely controlled by VEGF-C and 
Nrp-2 interaction (11). Since we have demonstrated that a peptide inhibitor C-
furSema derived from the C-terminus of Sema3F is able to potently inhibit VEGF-
A and Nrp-1 interaction, we sought to determine whether C-furSema inhibits 
VEGF-C and Nrp-2 interaction as well. To define whether C-furSema works as a 
pan-Nrp inhibitor, we measured the inhibitory potency of the C-furSema in 
inhibiting VEGF-C and Nrp-2 interaction. Interestingly, C-furSema inhibits VEGF-
A binding to Nrp-1 affinity plate and VEGF-C binding to Nrp-2 affinity plate 
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equally well (Figure 3.4, IC50 = 20 ± 2 nM and 17 ± 1 nM, respectively). These 
data suggest that Sema3 represents a natural pan-Nrp inhibitor, and is able to 
inhibit both angiogenesis and lymphangiogenesis. 
 
Insights into distinctly furin processed forms of Sema3A  
There are between one and three furin cleavage sites in the C-terminal basic 
domain of different Sema3 family members, which produce natural variants with 
different spacing between C-terminal arginine and the dimeric helical region.  
While Sema3F possesses one furin consensus site, Sema3A possesses three.  
These three sites in Sema3A are known to be processed and important for 
function (84) (Figure 3.5).  To define the role of the multiple furin processing sites 
in Sema3A, we measured the inhibitory potency of the three processed variants 
of Sema3A. The furin-processed forms similar in length to C-furSema, Sema3A.2 
and Sema3A.3, are similar in potency (Figure 3.5, IC50 = 45 ± 12 nM and 27 ± 5 
nM, respectively).  Intriguingly, the shortest form, Sema3A.1 shows significantly 
reduced potency (IC50 = 1.1 ± 0.3 mM).  This form has the same amino acid 
sequence in both helical and C-terminal motifs, differing only in the spacing of 
these motifs.  These data suggest that furin site selection may represent a 
natural mechanism to produce Sema3A proteins with differing Nrp binding motif 
spacing, providing a unique mechanism for fine-tuning Sema3A/Nrp-1 binding. 
 
Discussion 
Our previous work demonstrated that a helical motif from the C-terminal basic 
domain of Sema3F contributes a second binding site for engaging Nrp-1, and it is 
both necessary and sufficient for enhancing the interaction between Sema3 and 
Nrp (97). It has been suggested that the motif adopts α-helix secondary structure 
and the helical nature of this motif is critical for Nrp binding. In order to define the 
helical nature of this motif, we have determined its structure. We have shown that 
this region adopts an α-helical structure, which is mainly stabilized by an 
intermolecular disulfide bond, consistent with our previous study. We also define 
molecular interactions that help stabilize the helical dimer.  
Nrp expression is observed in tumor, and its overexpression promotes tumor 
progression and metastasis in vivo for a variety of solid tumors (18, 103, 104). Indeed, 
Nrp-1 has been shown to be important for tumor angiogenesis and progression, 
while Nrp-2 is shown to promote tumor metastasis by increasing tumor-
associated lymphangiogenesis (105, 106). As a result, it is urgent to develop pan-
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Nrp inhibitor to inhibit both processes for optimal cancer therapy. Interestingly, 
we have demonstrated that a peptide inhibitor derived from the C-terminus of 
Sema3F named C-furSema is able to potently inhibit both VEGF-A binding to 
Nrp-1 and VEGF-C binding to Nrp-2 at similar IC50s. This represents a promising 
lead compound and may help the future rational design of potent pan-Nrp 
inhibitor. 
Our data demonstrate that the furin cleavage sites in the C-terminal domain of 
Sema3A are non-equivalent in terms of receptor binding. Thus, C-terminal furin 
processing functions not only as a binary activation mechanism but can produce 
activated species with differing physical properties.  Recent data indicate that this 
may have profound physiological implications.  Mutations of two different 
residues in the Sema3A.1 furin site, R730Q and R733H, have recently been 
shown to cause Kallmann’s syndrome, a serious genetic disease resulting from 
aberrant Sema3A dependent axon guidance (107).  Thus, differential furin 
processing of the C-terminal domain of Sema3 can have profound functional and 
physiological effects in human disease. Combined with these mechanistic 
insights, discovery of these disease associated mutations underline the 
importance of future studies of the regulation and function of differential furin 
processing of Sema3 in regulating Nrp engagement in both neuronal and 
cardiovascular signaling. 
 
Note: Part of this chapter has been published and is reproduced here for 
completeness of the dissertation (96). 
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Table 3.1. Data collection and refinement statistics  
Data collection   
Beamline  APS 22-ID  
Space group  P41  
Wavelength  1.00000 
Unit-cell parameters  88.817, 88.817, 181.575  
Unique reflections  38690 
Completeness (%)  90.6 (94.2)  
Resolution (Å)  2.6 (2.7-2.6)   
Rmerge (%)  7.6 (36.3)  
Redundancy  2.7 (2.6)  
I/σ(I) 10.6 (2.03)  
Refinement   
Resolution Limits (Å)  20.00-2.61  
# reflections/# to compute Rfree  36675/1936 
R (Rfree)  19.2 (22.5)  
# protein residues  684 
# solvent molecules  251 
Ramachandran   
Most favored  98.2 
Allowed  1.8 
Disallowed  0 
RMS deviation   
Bond, Å  0.006 
Angle, ° 0.970 
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Figure 3.1: The Nrp-1-Sema3F recombinant protein shows interesting 
tetrahedron like shape with each tip of the 4 Nrp-1 b1 domains (purple) pointing 
out. Sema3F helical motifs (green) are buried in the hydrophobic core formed by 
the bottoms of 4 Nrp b1 domains stacking together. 
 
 
 
 
 
 
 
 
 
 
35	  
	  
	  
	  
	  
 
Figure 3.2: Sema3F helical motif from the C-terminal basic domain extends out of 
the Nrp-1 b1 domain. 
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Figure 3.3: Sema3F helical motif from the C-terminal basic domain is mainly 
stabilized by an intermolecular disulfide bond, and to a less extent by further 
molecular interactions. 
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Figure 3.4:  C-furSema serves as a pan-Nrp inhibitor. C-furSema inhibits VEGF-
A binding to Nrp-1 affinity plate (Black line, IC50 = 20 ± 2) and VEGF-C binding to 
Nrp-2 affinity plate (grey line, IC50 = 17 ± 1 nM) at similar IC50s. 
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Figure 3.5:  Differential furin processing of Sema3A. Sema3A possesses a 
disulfide bonded dimeric helical motif followed by three furin consensus (RXXR) 
sites. These three distinct furin processing sites produce C-terminal domains of 
significantly different length and potencies. 
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CHAPTER FOUR 
 
The physical mechanism of Neuropilin function in VEGF signaling 
 
Introduction 
Vascular endothelial growth factor (VEGF) is a critical cytokine regulating the 
patterning of vascular structure during development, and homeostasis in adult in 
many systems and animal models (9, 10, 17, 108-110). Interestingly, VEGF was first 
identified as a tumor vascular permeability factor (VPF) because it is released by 
tumor cells with the ability to stimulate vascular leakage (4, 111, 112). VEGF was 
then reported to be central to tumor angiogenesis in many types of solid tumors 
(113-115), which is one of the most critical steps in tumor progression (116). Hyper-
activation of VEGF also causes aberrant vascularization in many other disease 
conditions, such as rheumatoid arthritis, diabetic retinopathy, and age-related 
macular degeneration (AMD) (117, 118).  
VEGF functions by binding two families of type I single transmembrane 
receptors, the receptor tyrosine kinase family members, VEGF receptor 1 
(VEGFR1) and VEGFR receptor 2 (VEGFR-2), and Neuropilin family members, 
Neuropilin 1 (Nrp-1) and 2 (Nrp-2) (64, 119-121). VEGFR-2 is considered the main 
VEGF signaling receptor under physiological and pathological conditions (16, 122). 
VEGFR-2-null mutation leads to the absence of blood vessels and failure of 
vasculogenesis in mouse embryos (16, 122). Nrp-1 works as a mandatory co-
receptor. The importance of Nrp-1 in angiogenesis is demonstrated in knockout 
mice, which show similar embryonic lethal phenotype to VEGFR-2 null mice (15, 
32). 
VEGFR-2 belongs to the class V receptor tyrosine kinase family composing of 
seven extracellular immunoglobulin-like (Ig) domains, a transmembrane domain 
and an intracellular portion containing a split kinase domain (123). VEGF ligands 
exist as disulfide-linked dimers that bind directly to the membrane distal domains 
(d1-3) of VEGFR receptors and cause receptor dimerization (124, 125). However, 
ligand binding is necessary but not sufficient for receptor activation.  Recent 
evidence showed that dimerization of the membrane proximal seventh Ig domain 
(VEGFR-2 D7) is critical for the activation of the intracellular kinase domain and 
subsequent signaling (126). Based on these data, it was suggested that ligand 
binding promotes VEGFR-2 D7 dimerization, which is critical for physically 
coupling ligand binding to receptor activation.   
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Nrp is a co-receptor with critical roles in vascular endothelial growth factor 
receptor 2 (VEGFR-2) mediated angiogenesis (13, 14, 64, 120). It has been long 
accepted that VEGF crosslinks Nrp-1 and VEGFR-2 to form a holo-signaling 
complex, which leads to full VEGFR-2 activation (120). Interestingly, accumulating 
data suggest that VEGFR-2 and Nrp-1 can directly interact in the absence of 
ligand (127, 128). For example, many groups have shown that this complex is pre-
formed in the absence of ligands in both receptor overexpression cell lines and 
primary cells (19, 128, 129), and this preformed complex is sufficient to enhance 
VEGFR-2 activation in the presence of VEGF (19). Further studies suggest that 
Nrp promotes VEGFR-2 activation via its extracellular domains. Indeed, it has 
been shown that the Nrp Fc fusion alone is sufficient to activate VEGFR-2 and 
promote vascular morphogenesis without VEGF added (130). It has also been 
reported that Nrp Fc fusion is able to rescue the vascular bed defects in Nrp null 
mouse embryos without VEGF, while adding excess VEGF alone cannot, which 
suggests a unique and distinct requirement of Nrp and VEGFR-2 coupling for full 
VEGFR-2 activation (24).  
Although the importance of Nrp in VEGF signaling pathway is well established, 
the physical mechanism and specific role of Nrp is not understood. In order to 
define the role of Nrp in VEGFR activation, we have first determined the crystal 
structure of VEGFR-2 membrane proximal domain 7 active dimer, and then 
demonstrated that Nrp is directly physically coupled to VEGFR-2 D7 in the 
absence of VEGF-A. This interaction between Nrp-1 and VEGFR-2 D7 is further 
shown to be mediated by Nrp-1 b1b2 domain. To provide physical basis of this 
interaction, we have then determined the structure of Nrp-1 b1b2 domain and 
VEGFR-2 D7. Together with the biochemical results, we have demonstrated that 
VEGFR and Nrp are directly coupled to each other via the interaction between 
Nrp b1b2 domain and VEGFR-2 D7, and decoupling these two receptors is 
sufficient to inhibit VEGF signaling. This suggests a new mechanism of Nrp in 
VEGFR activation. 
	  
Methods 
Protein production and purification 
We have expressed, purified, and crystallized domain 7 from mouse VEGFR-2 
(residues 663-755).  The protein was expressed as a 6XHis-tagged protein from 
pET-28 (Novagen) in Rosetta-gami2(DE3) cells.  Cells were grown at 37°C in 
Terrific-Broth media supplemented with 50mg/mL kanamycin.  When cells 
reached OD600=1.5, they were placed on ice for fifteen minutes, induced with 
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1mM isopropyl-D-thiogalactopyranoside (IPTG), and incubated for sixteen hours 
at 16°C.  This protocol yielded approximately 10mg/L of soluble, correctly folded, 
and disulfide linked protein without the need for refolding.  Cells were harvested 
and lysed using lysozyme and sonication.  Protein was purified over His-Select 
affinity resin (Sigma-Aldrich).  The 6XHis-tag was removed by incubation with 
thrombin (10U/mg protein) overnight at room temperature.  Protein was finally 
purified using size-exclusion chromatography (20mM Tris, pH=7.5, 100mM NaCl) 
yielding >95% pure protein.   
A fusion of rat Nrp-1 b1b2 (residues 274-586) linked to mouse VEGFR-2 D7 
(residues 663-755) with an intervening Spe1 restriction site was introduced into 
the Nde1/EcoR1 sites of pET28b (Novagen). The protein was expressed in a 
similar way as mouse VEGFR-2 domain 7 construct discussed above as a 
6XHis-tagged protein from pET-28 (Novagen) in Shuffle cells. This protocol 
yielded approximately 3 mg/L of soluble, correctly folded, and disulfide linked 
protein without the need for refolding. Protein was first purified over His-Select 
affinity resin (Sigma-Aldrich).  The 6XHis-tag was cleaved by incubation with 
thrombin (10U/mg protein) overnight at room temperature. Protein was finally 
purified using heparin chromatography to remove the 6XHis-tag. 
Alkaline Phosphatase (AP) fused Nrp and VEGFR-2 constructs were produced 
from Chinese Hamster Ovary (CHO) cells, and purified with heparin 
chromatography and His-Select affinity resin respectively similarly to previously 
reported (96). 
 
Crystallization 
VEGFR-2 D7 protein was diluted 1/10 with MilliQ water and concentrated to 
10mg/mL. Hanging-drop vapor diffusion trays were set up using a Mosquito 
crystallization robot with equal volume protein and reservoir solution.  Single high 
quality crystals were obtained after two weeks at room temperature using a 
reservoir solution of 0.1M Succinic acid pH 7.0, 15% (w/v) PEG 3350.  Crystals 
with overall dimensions of approximately 200 X 100 X 50 mm were rapidly 
soaked in reservoir solution supplemented with 15% ethylene glycol and flash 
frozen in liquid nitrogen. 
To crystalize Nrp-1 b1b2 and VEGFR-2 D7 fusion protein, hanging-drop vapor 
diffusion trays were set up for Nrp-1 b1b2 and VEGFR-2 D7 fusion protein using 
a Mosquito crystallization robot with volume protein and reservoir solution ratio 
3:1.  Single high quality crystals were obtained after two months at room 
temperature using a reservoir solution of 0.1m MES pH6.5, 12% (w/v) PEG 20K.  
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Crystals with overall dimensions of approximately 100 X 100 X 100 mm were 
rapidly soaked in mineral oil and flash frozen in liquid nitrogen. 
 
Structure determination  
Diffraction data to 1.2 Å resolution for VEGFR-2 D7 and 2.9 Å for Nrp-1 b1b2 and 
VEGFR-2 D7 fusion protein were collected at the Southeast Regional-
Collaborative Access Team (SER-CAT) 22-ID beamline at the Advanced Photon 
Source (APS) (Table 4.1 and 4.2).  Data were indexed, integrated, and scaled 
using HKL2000 (98).  Intensity data were converted to structure factors using 
Truncate in the CCP4i suite (131).  The crystal structure of VEGFR-2 D7 was 
determined by molecular replacement using PHASER (132), with the first Ig-
domain of MuSK (PDB 2IEP) as the search model (133). This 1.2 Å VEGFR-2 D7 
structure and a previously published rat Nrp-1 b1b2 domain structure were used 
as a molecular replacement search model for Nrp-1 b1b2 domain and VEGFR-2 
D7 using CCP4i (47).  Iterative model building and refinement were accomplished 
using Coot (99) and Refmac5 (100).  TLS groups for use in refinement were derived 
from TLSMD (134). The final model of the VEGFR-2 D7 dimer included all residues 
and was fully refined with Rwork/Rfree=18/21 (Table 4.1). The Nrp-1 b1b2 and 
VEGFR-2 D7 fusion protein was refined with Rwork/Rfree=23/28 (Table 4.2). 
 
Structural analysis 
Analysis of the dimer interface was accomplished using PISA (135), multiple 
sequence alignment was performed using ClustalW (136), stereochemistry of the 
model was analyzed using Mol-Probity (101), and molecular graphics were 
prepared using Pymol (102). 
 
In vitro binding assays 
Plate-based inhibition assays were performed similarly as discussed in chapter 2 
and previously reported (40).  Briefly, 41 mM para-nitrophenol phosphate (p-NPP) 
hydrolyzed/min/µL of AP-Nrp constructs were dialyzed into binding buffer (20 mM 
Tris, pH 7.5/50 mM NaCl), incubated with Nrp-1 affinity plates for 1 hour at 25°C, 
washed three times with PBS-T (0.01M Phosphate buffered saline, 0.1% Tween 
20, pH 7.4), incubated with PBS-T for 3 minutes, aspirated, and developed by 
addition of 100µL of 1X alkaline phosphatase pNPP substrate (88) followed by 
quenching with 100µL of 0.5N NaOH. AP activity was quantitatively measured at 
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405nm using a SpectraMax M5 instrument (Molecular Devices, Sunnyvale, CA). 
For Nrp-1 b1b2 and VEGFR-2 D7 binding affinity measurement and VEGFR-2 
D7 mutagenesis experiment, AP-VEGFR-2 D7 was added to Nrp-1 b1b2 coated 
plate. Binding curves were fit using a one-site specific binding mode to determine 
Kd (Graphpad Prism). Experiments were performed in triplicates and results 
reported as the mean ± 1 standard deviation.  An unpaired t-test was used to 
compare results. 
 
In vitro antibody blocking assay 
A previously published mouse derived anti-human Nrp-1 monoclonal antibody 
was further characterized with in vitro antibody blocking assays (137). Briefly, Nrp-
1 b1b2 domain affinity plates were pre-incubated with 0.1 µM of anti-Nrp-1 
antibody in binding buffer (20 mM Tris, pH 7.5/50 mM NaCl) for 0.5 hour at 25°C. 
After incubation, 410 µM para-nitrophenol phosphate (p-NPP) hydrolyzed/min/µL 
of AP-VEGF-A or 41 mM para-nitrophenol phosphate (p-NPP) hydrolyzed/min/µL 
of AP-VEGFR-2 D7 was added to the plates and incubated for another 0.5 hour 
at 25°C. The plates were then washed, developed and read the same way as 
described above in In vitro binding assays. For control plates, 15 µg/ml of BSA 
was added for the pre-incubation. 
 
In situ inhibition assays 
HUVEC cells were grown with Endothelial Cell Growth Media Kit (Lonza, 
Walkersville, MD) supplemented with 1% Pen/Strep in 6-well cell culture plates to 
70% confluence. Cells were then serum starved for 16 hours in Endothelial Cell 
Basal Growth Medium-2 (EBM-2) (Lonza, Walkersville, MD). Anti-Nrp-1 
monoclonal antibody was first dialyzed into PBS, resuspended in EBM-2, added 
to HUVEC cells at a final concentration of 10 µM, and incubated for 90 minutes at 
37°C (137).  Cells were then stimulated with 100 ng/ml VEGF-A (R&D Systems, 
Minneapolis, MN) for 3 minutes. After 3 minutes, media was removed and cells 
solubilized in RIPA buffer supplemented with phosphatase and protease inhibitor 
(Roche, Germany).  Total VEGFR-2 and VEGFR-2 phosphorylation was 
determined by western blotting using 55B11 and 19A10 antibodies (Cell 
Signaling, Danvers, MA), respectively, at a 1:1000 dilution followed by goat anti-
rabbit HorseRadish Peroxidase (HRP) conjugated secondary antibody at 
1:20000 dilution (sc-2301, Santa Cruz).  The SuperSignal West Femto 
chemiluminescence (ECL) detection system (Thermo Fisher Scientific, Rockford, 
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IL) was used for detection of immunoreactivity on X-ray films (HyBlot CL; Denville 
Scientific, Inc. Metuchen, NJ).  
 
Results 
The physical basis of VEGFR-2 D7 dimerization and its significance  
VEGF signal is delivered into the cell via VEGFR-2 mediated tyrosine kinase 
cascade under physiological and pathological conditions, and it is suggested that 
ligand binding induced dimerization of the membrane proximal seventh Ig domain 
of VEGFR-2 (VEGFR-2 D7) is critical for physically coupling ligand binding to 
receptor activation (126). In order to directly visualize this dimer interface, we have 
crystalized mouse VEGFR-2 D7. Interestingly, this domain adopts the previously 
defined active dimer conformation in the crystal structure (126), with 518 Å2 buried 
surface per subunit at the interface (Figure 4.1A and 4.1B). Four elements of the 
structure contribute to the dimerization interface: the loops between sheets A’-B, 
C’-D, E-F, as well as the single helix, a R724, from the E-F loop, is central to the 
dimer interface, contributing approximately 36% of the interfacial surface (Figure 
4.1C).  R724 forms two intermolecular salt bridges with D708 and D728, 
contributed from the C’-D loop and	  α, respectively.  Additionally, the side-chain 
NH1 of R724 is oriented to form an intermolecular hydrogen bond with the 
carbonyl of the other R724 across the dimer.  S709, from the C’-D loop, also 
makes intermolecular contacts, contributing approximately 20% of the dimer 
interfacial area (Figure 4.1C).  The side-chain hydroxyl of S709 is oriented to 
form an intermolecular hydrogen bond with the side-chain hydroxyl of T681 and 
the backbone amide of R724. This structure presented here is consistent with the 
human VEGFR-2 D7 dimer model deduced previously (126), but provides a 
significantly more detailed and accurate picture of the nature of, and residues 
contributing to, the VEGFR-2 D7 dimer. 
While D7 dimerization is thought to be critical for physically coupling ligand 
binding to VEGFR-2 activation, the dimerization interface must necessarily be 
limited to avoid ligand independent activation of signaling. Indeed, the VEGFR-2 
D7 dimer structure we presented here is consistent with this requirement, with 
only 518 Å2 buried surface per subunit at the interface. Interestingly, this notion 
is also supported by previous studies. It has been initially shown that D7 dimer 
formation is beyond detection by analytical ultracentrifugation even at 100 µM of 
VEGFR-2 D7 protein, suggesting that the dissociation constant of this interaction 
is larger than 100 µM (126). A further study has then suggested that the 
dimerization of domain 4-7 of VEGFR-2 is actually energetically unfavorable (138). 
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As a result, the stable dimerization of membrane proximal domain cannot be 
easily induced by the ligand-mediated dimerization of D2 and D3, and thus is the 
limiting step in VEGFR activation. Since Nrp ectodomain has been demonstrated 
to directly interact with VEGFR-2 and is both necessary and sufficient for 
VEGFR-2 mediated endothelial cell activation (127, 130), we hypothesized that Nrp 
extracellular domains potentiate VEGFR-2 signaling by promoting dimerization of 
membrane proximal domain 7 via direct receptor coupling.   
 
Nrp-1 b1b2 domain is directly coupled to VEGFR-2 D7 
In order to test this hypothesis, a plate binding assay using purified VEGFR-2 D7 
was performed. As shown in Figure 4.2A, Nrp-1 ectodomain clearly binds to 
VEGFR-2 D7 coated plate. Since the MAM/c domain of Nrp-1 has been 
suggested to form a dimer, we predicted that Nrp-1 MAM/c domain dimer 
facilitates the dimerization of VEGFR-2 D7 and thus leads to full VEGFR-2 
activation. To test this hypothesis, we have mapped the physical interaction 
between Nrp-1 extracellular domains and VEGFR-2 D7 using a battery of Nrp-1 
extracellular domain truncation constructs. To our surprise, VEGFR-2 D7 directly 
binds to Nrp-1 b1b2 domain, but not MAM domain. To further determine the 
binding affinity this interaction, we measured the dose-dependent binding of 
VEGFR-2 D7 onto Nrp-1 b1b2 domain coated plate and determined the 
dissociation constant (Kd=15.3 ± 1.6 µM) (Figure 4.2B).  
In order to define the physical basis of the interaction, we crystallized the fusion 
protein of VEGFR-2 D7 and Nrp-1 b1b2 domain. High quality crystals of this 
recombinant protein have been obtained and data collected to 2.92 Å (Table 4.2). 
The structure has been fully refined with one recombinant protein dimer in the 
asymmetric unit (Table 4.2). VEGFR-2 D7 makes direct physical contact with 
Nrp-1 b1b2 domain. The overall structure adapts a butterfly shape with two 
VEGFR-2 D7 molecules arranged as a parallel dimer (Figure 4.3A) in the center. 
The VEGFR-2 D7 dimer observed in this structure is consistent with the mouse 
VEGFR-2 D7 dimer, discussed above, with a 0.7-Å rmsd over 186 residues. The 
two Nrp-1 b1b2 domains adopt the typical discoidin family β-sandwich fold in a 
similar confirmation to each other with a 0.8-Å rmsd over 312 residues, and are 
also arranged as parallel dimer outside and in parallel orientation to VEGFR-2 D7 
dimer. As a result, the two VEGF-A binding sites in the tips of Nrp-1 b1 domains 
are separated by the VEGFR-2 D7 dimer with a distance of about 90 Å. The 
bottoms of Nrp-1 b2 domain are also apart from each other, and form a cleft for 
the seven-residue loop located between the end of VEGFR-2 D7 and the 
predicted beginning of the VEGFR-2 transmembrane helix.  
46	  
	  
Residues at the VEGFR-2 D7 and Nrp-1 b1b2 domain interface are well resolved 
and include interactions involving both backbone and side-chains. L732 from F 
strand of VEGFR-2 D7 establishes hydrophobic interactions with residue L332, 
M434, V438, and V465 of Nrp-1, which form a hydrophobic patch at the 
boundary of b1 and b2 domain (Figure 4.3B). Outside this hydrophobic patch, 
D747 from G strand of VEGFR-2 D7 forms a critical salt bridge with R334 from 
strand 3 of Nrp-1 b1b2 domain. These interactions contribute near 30% of the 
heterodimer interfacial area. The heterodimer is further enhanced by a hydrogen 
bond between K727 from the E-F loop of VEGFR-2 D7 and Q446 from the first 
strand of Nrp-1 b2 domain. There are also other hydrogen bond interactions 
involving backbone amine and carbonyl groups. H287 from the N-terminus of 
Nrp-1 b1 domain makes hydrogen bonding with the backbone carbonyl group of 
I667 from A strand of VEGFR-2 D7. The backbone NH of I752 from G strand of 
VEGFR-2 D7 and carbonyl group of S439 from the beginning of Nrp-1 b2 domain 
also form a hydrogen bond.  
Many of the observed residues at the interface are strongly conserved among 
different isoforms of VEGFRs and Nrps, and cross species.  In particular, L732 
and L749 from VEGFR-2 D7 are highly conserved among VEGFR-1, 2 and 3, 
and cross all species (Figure 4.4A). L332, M434, V438, and V465 from Nrp-1 
b1b2 domain that form an essential hydrophobic patch at the boundary of Nrp-1 
b1 and b2 domain are also highly conserved in Nrp-1 and Nrp-2, and cross 
species. The observed conservation of the interfacial residues suggests that this 
hetero-dimerization represents a general mechanism of Nrp for interacting with 
the membrane proximal domains of VEGFRs in the activated state.  
To confirm the contribution of these critical residues to binding, we introduced 
and analyzed single amino acid mutations in VEGFR-2 D7 (Figure 4.4B). To 
dissect the contribution of this conserved major hydrophobic interaction between 
VEGFR and Nrp, we mutated VEGFR-2 L732 and L749 into arginine, both of 
which poke to the center of a hydrophobic patch on Nrp-1 composed of L332, 
M434, V438, and V465. Either single amino acid mutation greatly decreases the 
interaction between VEGFR-2 D7 and Nrp-1 b1b2 domain as demonstrated by 
plate binding assay. All these mutants were not structurally deleterious as 
determined by circular dichroism (Figure 4.5). 
 
Blocking Nrp-1 b1b2 domain and VEGFR-2 D7 intearaction inhibits signaling 
Based on computer modeling, it has been predicted that decoupling VEGFR-2 
and Nrp is a more efficient way of inhibiting VEGF signaling compared to 
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blocking ligand binding (139). As a result, we hypothesized that decoupling 
VEGFR-2 D7 and Nrp-1 b1b2 domain is sufficient to inhibit VEGF signaling. In 
order to test this hypothesis, we have identified and further characterized an anti-
human Nrp-1 b1b2 domain mouse monoclonal antibody (137). Since Nrp-1 b1b2 
domain has been demonstrated to be able to bind VEGF-A (47), we first tested 
whether this antibody interferes ligand and receptor interaction using Nrp-1 b1b2 
domain coated plates. As expected, AP-VEGF-A binds almost equally well to 
Nrp-1 b1b2 domain coated plates with or without anti-Nrp-1 antibody pre-
incubation (Figure 4.6A). This strongly suggests that this anti-Nrp-1 antibody 
does not block VEGF and Nrp-1 b1b2 domain interaction.  
In order to test whether this antibody blocks VEGFR-2 D7 and Nrp-1 b1b2 
interaction, AP-VEGFR-2 D7 was utilized as a ligand to interact with Nrp-1 b1b2 
domain coated plates. Robust binding was observed when AP-VEGFR-2 D7 was 
added to Nrp-1 b1b2 domain coated plates (Figure 4.6A). Strikingly, anti-Nrp 
monoclonal antibody pre-incubation is able to almost fully inhibit this interaction, 
demonstrating that this antibody specific blocks VEGFR-2 D7 and Nrp-1 b1b2 
interaction without affecting the binding of VEGF-A to Nrp-1 (Figure 4.6A). In 
order to evaluate the effect of decoupling VEGFR-2 D7 and Nrp-1 b1b2 domain 
on VEGF signaling in situ, we examined the ability of this antibody to inhibit 
VEGF-A stimulated VEGFR-2 phosphorylation of Y1175 in HUVEC cells (Figure 
4.6B). As expected, when the cells were stimulated with VEGF-A, robust 
VEGFR-2 Y1175 phosphorylation was observed. However, when the cells were 
pre-incubated with this monoclonal anti-Nrp-1 antibody, potent inhibition of 
VEGF-A mediated VEGFR-2 activation was observed while the level of total 
VEGFR-2 and Nrp-2 was not changed. This demonstrated that decoupling these 
two receptors is indeed sufficient to inhibit VEGF signaling, suggesting a novel 
strategy for inhibiting VEGF signaling. This monoclonal antibody thus represents 
a novel class of VEGF inhibitor. 
  
Discussion 
Nrp has long been accepted as a mandatory co-receptor for VEGF mediated 
angiogenesis (15, 18). However, little is known about the specific role of Nrp and 
the physical basis of Nrp function in this pathway. The crystal structure of the 
Nrp-1 b1b2 domain and VEGFR-2 D7 protein complex presented in this study 
provides a model of intermolecular contacts required to physically couple ligand 
binding to full VEGFR activation. Core residues at the Nrp-1 b1b2 domain and 
VEGFR-2 D7 heterodimer interface are conserved among all Nrp and VEGFR 
family members, and cross species, suggesting that this interaction is a key 
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feature of all Nrp and VEGFR family members and is a general mode to couple 
VEGF ligand binding to receptor activation. Since it has been demonstrated that 
VEGF-C is able to mediate heterodimerization of VEGFR-2 and VEGFR-3, 
thereby producing a singling complex with unique activity (140), the strong 
similarity between VEGFR-2 D7 and VEGFR-3 D7 suggests that D7 
heterodimerization may be utilized for activation. Additionally, since both Nrp-1 
and 2 interact with VEGF-C, a VEGF-C signaling holocomplex composing of 
VEGF-C, VEGFR-2 and VEGFR-3 heterodimer, Nrp-1 and Nrp-2 heterodimer 
could form and deliver unique signal. 
The VEGFR-2 D7 dimer is parallel in orientation leading to alignment of the C-
termini, one essential requirement for a productive signaling dimer. Two Nrp-1 
b1b2 domains also adopt a parallel dimer outside of VEGFR-2 D7 dimer with the 
C-termini Nrp-1 b1b2 domains forming a cleft about 18 Å deep.  Since there are 
seven additional residues located between the end of VEGFR-2 D7 and the 
predicted beginning of the transmembrane helix and recent reports have 
demonstrated that the transmembrane domain of VEGFR-2 requires a specific 
dimeric confirmation to align the intracellular kinase domains, the Nrp-1 b1b2 
domain likely functions to orient the VEGFR-2 D7 domain, and may also interact 
and orient the additional seven residues between the end of VEGFR-2 D7 and 
the predicted beginning of the transmembrane helix as well. This would help the 
transmembrane domain of VEGFR-2 adopt a specific confirmation and position 
the intracellular kinase domains to full activated state. Interestingly, in this 
VEGFR-2 D7 and Nrp-1 b1b2 receptor complex, two VEGF-A binding sites in 
Nrp-1 b1 domains are separated by 90 Å. Since the two Nrp-1 binding motifs in 
VEGF-A165 are located at the C-termini of two flexible heparin-binding domains, 
they have the potential to extend out and link two Nrp-1s that are up to 120 Å 
away. As a result, in our model, VEGF-A heparin binding domain could adopt a 
relative open conformation with two heparin domains extending out to bind Nrp-1 
b1 domains. This induces the dimerization of b1b2 domain, and thus orients and 
stabilizes the active VEGFR-2 D7 dimer. 
We have also demonstrated that an antibody blocking Nrp-1 b1b2 domain and 
VEGFR-2 D7 interaction is sufficient to inhibit VEGF signaling in HUVEC cells in 
situ. Interestingly, we have confirmed that this antibody does not affect the 
interaction between VEGF and Nrp-1 b1b2 domain. Since it has been predicted 
that decoupling VEGFR-2 and Nrp is a more efficient way of inhibiting VEGF 
signaling compared to block ligand binding (139), this antibody represents an 
attractive inhibitory modality for blocking VEGF signaling and belongs to a novel 
class of VEGF inhibitor. Indeed, this anti-Nrp-1 monoclonal antibody has 
previously been shown to inhibit proliferation, migration and invasion of glioma 
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cells both in vitro and in vivo (141), and more studies are needed to test the effect 
of this antibody in other cellular and animal models. Using inhibitory modalities 
decoupling Nrp-1 and VEGFR-2 interaction is an attractive strategy to inhibit 
VEGFR-2 signaling for many reasons. VEGF level has been reported to increase 
upon treatment with various VEGF signaling inhibitors (142-145), which serves as 
an unavoidable resistance mechanism for these reagents blocking ligand 
binding. Since the inhibitory effect of Nrp-1 and VEGFR-2 interaction decoupling 
reagents does not depend on blocking ligand binding, it was predicted to be less 
sensitive to VEGF concentration change (139). Finally, this novel class of inhibitor 
may provide unique opportunities to increase VEGF inhibition efficacy by 
combining with other VEGF signaling inhibitors, which is worth further 
investigation. 
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Table 4.1. VEGFR-2 D7 data collection and refinement statistics  
Data collection   
Beamline  APS 22-ID  
Space group  P212121  
Wavelength  1.00000 
Unit-cell parameters  49.634, 69.763, 71.651 
Unique reflections  71824 
Completeness (%)  91.3 (64.3)  
Resolution (Å)  1.2 (1.24-1.20) 
Rmerge (%)  9.9 (44.3) 
Redundancy  5.1 (3.0) 
I/σ(I) 13 (2.4) 
Refinement   
Resolution Limits (Å)  20.0-1.20 
# reflections/# to compute Rfree  68128/3621 
R (Rfree)  18.0 (21.0)  
# protein residues  192 
# solvent molecules  455 
Ramachandran   
Most favored  94.0 
Allowed  6.0 
Disallowed  0 
RMS deviation   
Bond, Å  0.02 
Angle, ° 1.80 
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Table 4.2. VEGFR-2 D7 and Nrp-1 b1b2 domain data collection 
and refinement statistics  
Data collection   
Beamline  APS 22-ID  
Space group  P43212  
Wavelength  1.00000 
Unit-cell parameters  77.320, 77.320, 430.253  
Unique reflections  25612 
Completeness (%)  90.6 (93.9)  
Resolution (Å)  2.92 (3.02-2.92)  
Rmerge (%)  16.0 (55.7)  
Redundancy  4.1 (3.9)  
I/σ(I) 20.3 (9.6)  
Refinement   
Resolution Limits (Å)  20.00-2.92  
# reflections/# to compute Rfree  25028/1329 
R (Rfree)  23.5 (27.6)  
# protein residues  819 
# solvent molecules  77 
Ramachandran   
Most favored  97.0 
Allowed  2.9 
Disallowed  0.1 
RMS deviation   
Bond, Å  0.006 
Angle, ° 0.88 
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Figure 4.1: Structure of the VEGFR-2 D7 dimer.  A) and B) VEGFR-2 D7 
crystallizes as a parallel dimer.  The two molecules in the dimer are similar, with 
a backbone r.m.s.d. of 0.6 Å. C) View of the VEGFR-2 D7 dimer interface with 
residues significantly contributing to the interface.   
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Figure 4.2: Physical coupling between Nrp and VEGFR-2 D7. A) Direct 
interaction is observed between VEGFR-2 D7 and Nrp-1. This interaction is 
mapped to Nrp-1 b1b2 domain using a plate based binding assay with purified 
proteins. B) The binding affinity of this interaction is further determined (Kd=15.3 
± 1.6 µM).  
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Figure 4.3: Crystal structure of VEGFR-2 D7 (cyan) and Nrp-1 b1b2 domain 
(green). A) Nrp-1 b1b2 interacts with VEGFR-2 D7 active dimer. B) A detailed 
view of the interaction interface shows hydrophobic interactions and salt bridge. 
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Figure 4.4: Critical residues in VEGFR-2 D7 for Nrp-1 b1b2 domain interaction 
are well conserved across species (shown in A), and are further confirmed to 
decrease VEGFR-2 D7 and Nrp-1 b1b2 domain interaction with mutagenesis 
(Shown in B).  
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Figure 4.5:	  VEGFR-2 D7 and mutants have similar CD spectrum, suggesting that 
mutations are not deleterious to protein structure.  
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Figure 4.6: Blocking VEGFR-2 D7 and Nrp-1 b1b2 domain interaction inhibits 
VEGF signaling. A)	  An anti-Nrp-1 b1b2 domain monoclonal antibody is shown to 
inhibit the interaction between VEGFR-2 D7 and Nrp-1 b1b2 domain in vitro 
without affecting the interaction between Nrp and VEGF-A. B) This monoclonal 
antibody is further shown to inhibit VEGF signaling in situ in human umbilical vein 
endothelial cells.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Hou-Fu Guo 2014 
58	  
	  
CHAPTER FIVE 
 
 Conclusions, significance and future directions  
 
General conclusions and significance 
In this series of studies I have focused on addressing the basic mechanism of a 
critical membrane receptor Nrp in vascular development. This was approached 
by physically dissecting domains and residues involved in the ligand receptor 
binding and receptor-receptor coupling using X-ray crystallography and other 
biophysical tools, followed by biochemical and cellular assays to validate the 
significance of these molecular interactions. I have determined a specific role and 
mechanism of Nrp in VEGF mediated angiogenesis, defined the ligand-receptor 
interaction mechanism between Sema3 C-terminus and Nrp. Taken together, 
these results advance our understanding of VEGF signaling pathway, and 
identify novel strategies to inhibit Nrp function. 
 
Nrp and VEGFR coupling in cis and trans VEGFR activation 
VEGF signals via VEGFR mediated tyrosine kinase cascade under physiological 
and pathological conditions, and Nrp serves as an essential co-receptor to 
enhance VEGFR signaling. Although the importance of Nrp in VEGF signaling 
pathway is well established, the physical mechanism and specific role of Nrp is 
not understood, which represents one of the critical open questions in Nrp 
biology. In order to define the role and mechanism of Nrp in VEGFR activation, 
we have identified and characterized a critical interaction between Nrp b1b2 
domain and VEGFR-2 D7, and found that Nrp b1b2 domain functions as a 
molecular hub to integrate ligand binding and receptor coupling to receptor 
activation. Together with the cellular assay results, we have demonstrated that 
the observed direct receptor coupling is essential for correctly orienting the 
receptor dimer for trans-activation, and disrupting this interaction is sufficient to 
inhibit VEGF signaling. This work defines a unique physical basis of Nrp in 
VEGFR activation and disrupting this receptor coupling represents a novel 
strategy for inhibiting VEGF signaling. 
In addition, my results indicate that the Nrp b1b2 domain, rather than the 
membrane proximal MAM domain, is coupled to VEGFR-2. Since there is a 
flexible loop between Nrp b1b2 domain and MAM domain, it is possible that Nrp 
from a non-endothelial cell type may act in trans to enhance VEGFR activation 
59	  
	  
on endothelial cells and thus stimulate angiogenesis. Indeed, it has been 
reported that fetal liver CD45+ hematopoietic cells derived Nrp-1 enhances 
VEGFR-2 activation on endothelial cells in the presence of VEGF, and increases 
endothelial cell proliferation (146). This trans-interaction has also been shown to 
be able to rescue vascular loss in the Nrp null P-Sp (paraaortic splanchnopleural 
mesodermal region) culture and promote angiogenesis in vivo. Since many tumor 
cells overexpress Nrp, tumor derived Nrp has also been suggested to promote 
endothelial cell survival and proliferation, and increase microvessel density (104). 
As a result, the work presented here provides a unique physical basis for Nrp 
mediated trans-activation as well. 
 
The basis of Nrp in angiogenesis 
The importance of Nrp in angiogenesis during development has been well 
demonstrated utilizing transgenic mice, which leads to embryonic lethality (15). 
Further analysis of these mice embryos suggests that Nrp null endothelial cells 
feature long distance random movement along existing capillaries, but defective 
directional movement toward VEGF, which results in reduction in vessel branch 
point and larger vessel diameter phenotype observed in Nrp null embryos (147). 
This is probably because Nrp null endothelial cells are unable to respond 
extracellular matrix bound VEGF next to them. Indeed, it has been well accepted 
that Nrp increases the directional migration toward VEGF when co-expressed 
with VEGFR-2 (18). Interestingly, using conditional knockout with Cre driven by 
the angiopoietin receptor TIE2, a recent work demonstrated that Nrp-1 was 
partially deleted only in a population of endothelial cells, while the rest of the 
population remain various levels of Nrp-1 (148). By analyzing these mice, they 
have shown that endothelial cells with higher level of Nrp-1 are more likely to be 
recruited to the tip of sprouting capillaries, and similar results were observed in 
Cre transgene driven by the PDGFb, a tip cell marker, suggesting that Nrp-1 
does provide an advantage for the cells to respond to VEGF gradient. However, 
the mechanism of the sensitizing effect of Nrp-1 to VEGF gradient is not clear, 
although many mechanisms could contribute to it. 
 
Nrp increases the affinity of VEGF to VEGFR-2 
The privilege of Nrp-1 expressing cells on VEGF sensing and the potentiation 
effect of Nrp-1 on VEGF mediated directional migration could simply be due to its 
ability to increase the binding of VEGF to VEGFR-2. Indeed, this idea is 
supported by early work, however, this study was semi-quantitative and has not 
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determined the binding affinities between VEGF and VEGFR expressing cells 
with and without Nrp (18). Later follow-up studies did measure their binding 
affinities but produce controdictory results. Some showed that Nrp does enhance 
the binding of VEGF to VEGFR-2 (19), but others failed to observe any obvious 
changes in the interaction between VEGF and VEGFR-2 in the presence or 
absence of Nrp although many cell lines were used (128). As a result, it is still not 
clear whether Nrp enhances the interaction between VEGF and VEGFR-2, and 
whether this mechanism is important for VEGF signaling. More research is 
definitely needed to figure out the reasons of binding affinity disparities and the 
contribution of Nrp in increasing the affinity between VEGF and its major 
signaling receptor VEGFR-2.  
 
Nrp increases the efficiency of signal transmission 
The advantage of Nrp-1 expressing cells on VEGF sensing and the potentiation 
effect of Nrp-1 on VEGF mediated directional migration could also due to its 
ability to increase the efficiency of signal transmission across the membrane, and 
thus VEGFR-2 down stream signaling. Indeed, at the molecule level, Nrp greatly 
potentiates VEGF mediated VEGFR-2 signaling in endothelial cells. In the 
presence of Nrp, not only the amplitude but also the duration of VEGFR-2 
phosphorylation upon VEGF stimulation is enhanced (19, 87). This is a general 
effect and has not been shown to be limited to any specific VEGFR-2 intracellular 
tyrosine phosphorylation sites. Since VEGFR-2 tyrosine phosphorylation is the 
signal that the cells detect intracellularly, by increasing the efficiency of signal 
transmission across the membrane and enhancing the VEGFR-2 
phosphorylation, endothelial cells with Nrp are able to detect shallower VEGF 
gradient that could not be sensed otherwise (Figure 5.1). The structure work 
described in chapter 4 presents a new working model to explain the mechanism 
of Nrp in enhancing the efficiency of signal transmission across the cell 
membrane. Our structures suggest that VEGFR-2 D7 dimerization process is a 
bottleneck in VEGF signal transmission across the cell membrane and Nrp b1b2 
domain facilitates this process by stabilizing VEGFR-2 D7 dimer especially after 
ligand binding. However, further studies with other cellular and animal models, 
single molecule techniques, and etc. are still needed to verify the significance of 
this model in explaining the mechanism of Nrp in VEGF signaling. 
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VEGFR-2 trafficking 
Alternatively, it is also suggested Nrp potentiates VEGFR-2 signaling by 
modulating VEGFR-2 receptor trafficking (149). It has been shown that in the 
presence of Nrp and VEGF, Nrp promotes VEGFR-2 recycling through Rab5, 
Rab4, and Rab11 recycling pathway, prevents VEGFR-2 degradation, and thus 
prolongs the signaling time. Moreover, it has then demonstrated that VEGF is 
required for holding the complex together, since VEGF-A166b, an isoform does not 
bind Nrp, fails to induce such enhanced signaling effect. The intracellular domain 
of Nrp-1 was also shown to be necessary for VEGFR-2 receptor trafficking, since 
the deletion of Nrp intracellular domain abolishes the prolonged VEGFR-2 
signaling. These VEGFR-2 trafficking changes introduced by Nrp are interesting 
and the biological relevance of these changes is still waiting for validation using 
animal models. Interestingly, another recent study demonstrated that Nrp 
intracellular domain is able to accelerate the trafficking of endocytosed VEGFR-2 
from Rab5+ to EAA1+ endosomes, and thus enhance VEGFR-2 signaling by 
decreasing PTPN1 (PTP1b)-mediated VEGFR-2 dephosphorylation (26). This 
enhancing effect of Nrp on VEGFR-2 signaling has then been suggested to play 
a role in arteriogenesis during vascular development. It will be interesting to 
study the role of this Nrp mediated trafficking change in other biological settings. 
In summary, the role of Nrp in modulating VEGFR-2 trafficking is still emerging 
and it will be interestingly to determine the whole picture of the VEGFR-2 
trafficking changes introduced by Nrp. 
 
Nrp coupling to other receptors 
Finally, Nrp has been shown to modulate VEGF signaling by coupling to other 
cell surface receptors, such as integrins. Indeed, Nrp-1 is expressed in 
pancreatic ductal adenocarcinomas, and has been suggested to associate with 
β1 integrin to promote cell invasion (150). Likewise, Nrp-2 has also been indicated 
to interact with α5 integrin and enhance tumor cell extravasation and metastasis 
(151). However, Nrp and integrin association does not always lead to enhanced 
cell migration. For instance, αvβ3 integrin and Nrp-1 interaction has been 
suggested to inhibit angiogenesis probably by sequestering Nrp-1 from the active 
VEGF/VEGFR-2 signaling complex (152). These data have demonstrated that Nrp 
and integrin receptors function cooperatively to regulate cell migration, and 
further investigation is definitely needed to determine the importance of these 
functional interactions in other animal models and the extent of these 
associations in modulating VEGF gradient sensing in endothelial cell. These data 
will stimulate more interest in understanding the detailed nature of the physical 
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coupling between Nrp and integrins in the future. Since the intracellular adaptor 
protein RGS-GAIP-Interacting Protein C-terminus (GIPC) has been shown to 
bind to the intracellular domain of both Nrps and integrins (153-155), the possibility 
exists that GIPC plays a role in the functional coupling between Nrp and integrin, 
which is worth further investigation.  
 
VEGF and Sema3 C-terminus competes for binding to Nrp 
Vascular development is regulated by the balance of pro-angiogenic cytokines 
exemplified by VEGF-A, and angiogenesis inhibitor, such as Sema3F (77, 78, 156).  
The anti-angiogenic activity of Sema3F was shown to result from direct 
competition between Sema3F and VEGF-A for binding to their shared C-terminal 
arginine-binding pocket in the Nrp b1 domain (40). Previously, it has been shown 
that VEGF-A C-terminal residues encoded by the exon seven interacts with the 
L1 loop of the Nrp-1 b1 domain, enhancing binding and selectivity of this 
interaction (46). Interestingly, the work presented here demonstrated that Sema3 
family members engage Nrp-1 utilizing two distinct regions in their C-terminal 
domain, a C-terminal arginine and upstream helical region.  This synergistic 
engagement results in potent competitive binding to Nrp-1 that antagonizes 
VEGF binding and cellular activation. These results define a unique high-affinity 
hetero-bivalent ligand-receptor interaction mechanism between Sema3 C-
terminus and Nrp, and determine the basis of Sema3F mediated anti-angiogenic 
activity, which may help rational Nrp inhibitor design.   
In order to define the nature of this motif, we have determined its structure by X-
ray crystallography. We have shown that indeed this structure is a parallel helical 
dimer, which is mainly stabilized by an intermolecular disulfide bond. Since this 
helical dimer has been suggested to contribute as a second binding site to 
engage Nrp b1 domain, Sema3 C-terminal basic domain may bind and bring two 
Nrp b1 domains to close proximity. It will be interestingly to characterize the 
detailed b1 domain organization upon Sema3 binding. This may be distinct from 
the b1 domain organization during VEGF signaling. Knowing this difference in b1 
domain organization may help develop reagents to selectively inhibit or facilitate 
VEGF or Sema3 stimulated Nrp signaling. 
 
Explore the non-canonical roles of Nrp in other cell types 
Besides Nrp’s classical functions in axon guidance and angiogenesis in neurons 
and endothelial cells, effort has been made to elucidate the non-canonical 
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signaling and novel roles of Nrp in a variety of tissues. For example, VEGF 
autocrine signaling pathway has been shown to be important for tumor stem cell 
maintenance, tumor cell survival and drug resistance in multiple cancer types (157-
160). Recently, it has been reported that hypoxia-induced Sema3A attracts tumor-
associated macrophages into tumor hypoxic niche by engaging Nrp-1, plexin and 
VEGFR1 signaling complex (161). Interestingly, it was originally believed that, out 
of seven semaphorin families, only class 3 semaphorin members require Nrp as 
a receptor. However, as an exception to dogma, immune cell expressed Sema4a 
has also been shown to be able to signal through regulatory T cell (Treg) 
expressed Nrp, which is required by Treg cells to inhibit anti-tumor immune 
responses and to cure established inflammatory colitis (162).  
Nrp-1 ligands VEGF and Sema3 have also been suggested to regulate platelet 
function. Platelets are small and anucleate blood cells, produced from bone 
marrow derived precursor cells named megakaryocytes and then released into 
blood stream. They are critical for maintaining a pressurized vasculature by 
rapidly responding to vascular damage. At the site of damage, platelets are 
exposed to agonists at the sub-endothelial layer, which bind to platelet cell 
surface receptor, and initiate platelet activation and thrombus formation to seal 
the damage. However, aberrant thrombosis is involved in the pathogenesis of 
heart attack and stroke. As a result, these cell surface receptors are major drug 
targets. 
Interestingly, it has been reported that VEGF potentiates thrombin-mediated 
platelet activation by enhancing VEGF receptor signaling (163). Sema3, on the 
other hand, inhibits platelet function by activating the Sema3-plexin pathway (164). 
However, a commercially available Sema3A/Fc fusion was used in this study as 
the ligand. In this fusion protein the C-terminal arginine, critical for high affinity 
Nrp-1 binding, is embedded as in the precursor form before furin processing. 
These assays and others have been interpreted based on their effect on other 
receptors in related pathways, such as VEGFR and plexin. As a result, whether 
Nrp-1 plays a role in platelet function is unknown. However, this research also 
raises another interesting question, that is, how is the pacifying effect of Sema3 
on platelets removed when platelet activation is necessary (165). Recently, platelet 
activation and thrombocytopenia (a potential ramification of platelet activation) 
was found in an anti-Nrp-1 antibody MNRP-1685A phase 1 and 1b clinical trial, 
which strongly argues a role of Nrp-1 in platelet activation and function (166). As a 
result, dissecting the contribution of Nrp ligands on platelet activation is an 
interesting topic for future study. 
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The biological significance of Nrp promiscuous ligand binding  
Based on this work and many others, it is well accepted that the Nrp-1 b1 
coagulation factor domain has a conserved C-terminal arginine-binding pocket 
that is the major binding site for interacting with its ligands (40, 47). Since many 
growth factors have a C-terminal arginine, such as VEGF, platelet-derived growth 
factor (PDGF), basic fibroblast growth factor (bFGF), hepatocyte growth factor 
(HGF), epidermal growth factor (EGF), and many proteases such as furin and 
thrombin produce a C-terminal arginine after their enzymatic cleavage, Nrp has 
the potential to interact with a battery of these cytokines. Indeed, many cytokines, 
such as VEGF, PDGF, and HGF, have been shown to be Nrp ligands. However, 
one of the interesting open questions of Nrp biology is what is the physiological 
relevance of Nrp promiscuous ligand binding. 
Interestingly, since Nrp-1 is reported to have sorting ability in endothelial cells 
(149) and is able to interact with 9 out of 14 major pro-angiogenic cytokines in 
platelets (64, 167-169), it is possible that Nrp-1 may function as a general sorting 
receptor ultimately serving to maintain the balance of pro and anti-angiogenic 
cytokine storage in some cell types, such as platelets. Indeed, many Nrp-1 
ligands, such as VEGF and bFGF, are not produced during platelet biogenesis 
but instead are taken up by circulating platelets presumably by receptor mediated 
endocytosis, but the receptor that mediates this process is unknown (64, 170, 171). 
As a result, exploring the role of Nrp in regulating platelet cargo loading is an 
interesting future direction in Nrp field.  
It is possible that platelet Nrp may modify angiogenesis by tuning the balance 
between pro and anti-angiogenic cytokine storage in platelets. Indeed, platelets 
store a variety of bioactive molecules in their three different granules: α granules, 
dense granules, and lysosomes, and play an important role in angiogenesis (172, 
173). Upon activation, many angiogenic cytokines, such as VEGF, platelet-derived 
growth factor (PDGF), basic fibroblast growth factor (bFGF), epidermal growth 
factor (EGF), are released from one of the major granules, α granules (174-180). 
Release of these cytokines has been shown to be important for wound healing 
after injury (181-183). Interestingly, platelet-loaded VEGF has been used to promote 
angiogenesis after surgeries and to treat stomach ulcers (182).  
Moreover, previous work has demonstrated that mild activation of platelets 
enhances granule cargo uptake into platelets, such as fibrinogen and serotonin 
(184, 185). It is thus possible that VEGF triggers mild platelet activation near 
vascular damage, thereby facilitates Sema3 uptake into platelets. This may serve 
to sequester excess Sema3, and normalize the angiogenesis cascade. As a 
result, it is worth the effort to assess the potential enhancing effect of VEGF on 
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Sema3 uptake. Finally, it has been argued that pro- and anti-angiogenic 
cytokines are differentially stored in α granules (178, 179). Since Nrp-1 mediates 
endocytosis of Sema3 and VEGF-A differently in endothelial cells (186), a 
differential Nrp-1-dependent endocytosis may underlie differential ligand uptake. 
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Figure 5.1: Schematic view of how the potentiation effect of Nrp-1 on VEGF 
signaling increase directional migration. Enhanced VEGFR-2 phosphorylation 
with the help of Nrp is more likely to reach the threshold for triggering directional 
cell migration.  
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